Effects of pasteurization and refrigerated storage on human milk neurobiomarkers concentrations by Peila, Chiara
  
 
Effects of pasteurization and refrigerated storage on
human milk neurobiomarkers concentrations
Citation for published version (APA):
Peila, C. (2018). Effects of pasteurization and refrigerated storage on human milk neurobiomarkers
concentrations. Maastricht: Datawyse / Universitaire Pers Maastricht.
https://doi.org/10.26481/dis.20180912cp
Document status and date:
Published: 01/01/2018
DOI:
10.26481/dis.20180912cp
Document Version:
Publisher's PDF, also known as Version of record
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 04 Dec. 2019
  
Effects of pasteurization and refrigerated storage 
on human milk neurobiomarkers concentrations  
 
 
 
 
 
Chiara Peila 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
© copyright Chiara Peila, Maastricht 2018 
 
Printing: Datawyse | Universitaire Pers Maastricht 
 
ISBN 978 94 9301 969 0 
  
  
 
Effects of pasteurization and refrigerated storage 
on human milk neurobiomarkers concentrations  
 
 
Dissertation 
 
 
to obtain the degree of Doctor at the Maastricht University, 
on the authority of the Rector Magnificus Prof.dr. Rianne M. Letschert 
in accordance with the decision of the Board of Deans, 
to be defended in public on 12th September 2018, at 10:00 hours 
 
 
 
 
by 
 
 
Chiara Peila 
  
 Promotors 
Prof. dr. D. Gazzolo (Ius Promovendi, Alessandria, Italy) 
Prof. dr. G.H.A. Visser (Utrecht) 
Prof. dr. E. Bertino (Torino, Italy) 
Assessment Committee 
Prof. dr. L. Zimmermann (chairman) 
Prof. dr. A. Kribs (Cologne - Germany) 
Prof. dr. T. Orlikowsky (Aachen, Germany) 
Prof. dr. B. Kramer 
Prof. dr. M. Spaanderman 
 
 
  
 5 
Content 
Chapter 1  11 
Introduction – Part 1 13 
Introduction – Part 2 The effect of Holder pasteurization on nutrients 
and biologically-active components in donor human milk: a review 27 
Chapter 2  Effects of Holder pasteurization on the protein profile of human milk 51 
Chapter 3  The effect of Holder pasteurization on Activin A levels in human milk 65 
Chapter 4  Holder pasteurization affects S100B concentrations in human milk 75 
Chapter 5  Heme oxygenase-1 in donor human milk 85 
Chapter 6  Human milk Adrenomedullin is unstable during cold storage at 4°c 95 
Chapter 7  Summary & conclusions 105 
Valorisation  115 
Curriculum Vitae 121 
Acknowledgements 125 
 
  
 6 
Abbreviations 
• Adrenomedullin (AM) 
• Carbon monoxide (CO) 
• Central nervous system (CNS) 
• Cerebral palsy (CP) 
• Cerebrospinal fluid (CSF) 
• Coefficient of variability (CV) 
• Donor milk (DM) 
• Enzyme-Linked Immunosorbent Assays (ELISA) 
• Epidermal GF (EGF) 
• Epidermal-like GF (HB-EGF) 
• Exclusive breastfeeding (EBF) 
• Exclusive human milk including expressed and donated breast milk (EHM-ED) 
• Extremely low birthweight (ELBW) 
• Gestational age (GA) 
• Granulocyte-Granulocyte-Colony Stimulating Factor (GCSF) 
• Growth factors (GF) 
• Heat shock proteins (HSPs) 
• Hemeoxygenase-1 (HO-1) 
• Heparin-Binding Hepatocyte GF (HGF) 
• Holder Pasteurization (HoP) 
• Human milk (HM) 
• Human Milk bank (HMB) 
• Human Milk Banking Associations (HMBA) 
• Immunoglobulins (Ig) 
• Information-dependent acquisition (IDA) 
• Insulin-like GF (IGF) 
• Interferon (IFN) 
• Interleukin (IL) 
• Italian Association of Human Milk Donor Banks (AIBLUD) 
• Low birthweight (LBW) 
• Macrophage Colony-Stimulating Factor (GM-CSF) 
• Macrophage Inflammatory Protein-1β (MIP-1β) 
• Mass spectrometry (MS) 
• Medium-chain fatty acids (MCFAs) 
• Monocyte Chemotactic Protein (MCP) 
• Necrotizing enterocolitis (NEC) 
• Neonatal intensive care unit (NICU) 
• Neurobiomarkers (NB) 
• No-Holder pasteurized (NO-HoP) 
 7 
• Nutritional quality (NQ) 
• One-dimensional electrophoresis (1DE) 
• Preterm birth (PB) 
• Radial Immunodiffusion Assays (RIA) 
• Transforming growth factor (TGF) 
• Tumor Necrosis Factor (TNF) 
• Vermont Oxford Network (VON) 
• Very low birthweight (VLBW) 
• Weight at birth (BW) 
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OUTLINE OF THE THESIS 
In Chapter 1, part 1, we provide an overview on the several biological aspects of the 
HM, its current techniques of heat and cold storage and the putative role of emerging 
neurobiomarkers in HM namely Activin A, S100B, HO-1 and AM. 
In Chapter 1, part 2, the state of art on the effect of Holder pasteurization (HoP) on 
nutrients and biologically-active components in DM is given. Results confirm that HoP 
affects several HM components and show the difficulties met to quantify the degrada-
tion level. Finally, proteins are more significantly affected by HoP but the results con-
cerning specific biologically active molecules remain uncertain. 
In Chapter 2 we evaluated the effect of HoP on the protein profile using a semi-
quantitative GeLC-MS analysis technique. Results showed that HoP affected about 30% 
of protein amount in the samples analyzed. The main changes concerned the colos-
trum, while no evident changes were observed in mature milk. This data offers addi-
tional support to the use of DM.  
In Chapter 3 we investigated the effects of HoP on the DM concentration of the neu-
rotrophic factor Activin A. The results showed that HoP does not affect Activin A con-
centrations in DM at different milk maturation degrees. The findings open-up to further 
investigations on other neuro-biomarkers assessment in HM and their pre-analytical 
stability according to storage procedures. 
Therefore, in Chapter 4 we investigated whether HoP procedure could somehow affect 
the neurotrophic S100B protein known for its thermos stability properties. Surprisingly, 
results showed that HoP affected S100B levels in DM, in transitional and mature milks, 
whereas no differences were detectable in colostrum. The explanation main reside in 
the HoP procedure itself (heat treatment at 62.5° for 30 minutes) suggesting that the 
duration of the procedure rather than temperature can cause protein’s degradation. 
In Chapter 5 we investigated the effects of HoP on a heat shock protein (HSPs) namely 
HO-1 known to participate in a cascade of events. HO-1 may play a role in development 
and regulation of the immune system. Our results showed that HoP did not affect HO-1 
in DM at different degrees of maturation. The finding is of relevance bearing in mind 
the role of HO-1 in the development and regulation of the immune system and of the 
gastro-intestinal tract. 
Finally, in Chapter 6 we evaluated the effect of cold storage of HM on the concentrations 
of a vasoactive and angiogenic factor namely AM. Results showed that AM concentra-
tions in HM are temperature and time-dependent. The present data suggest caution in 
the storage procedure and duration. The finding is of relevance taking into account the 
crucial role of the peptide in systemic vascular and multiorgan development  
In Chapter 7 we present the summary and conclusions of this thesis. 
  
  
 11 
Chapter 1 
 
  
 13 
Introduction – Part 1 
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The preterm infant  
Preterm birth (PB) is commonly defined as birth occurring <37 weeks gestational age 
(GA) and complicates 5-10% of all birth in Europe. In USA the rate is about 12–13% 
supporting the notion that PB varies from country to country (Figure1) [1]. 
PB can be classified according to GA in extreme PB (less than 28 weeks), severe PB 
(28–31 weeks), moderate PB (32–33 weeks), and late PB (34–36 weeks). PB can be also 
classified according to weight at birth (BW) as extremely low birthweight (<1000g, 
ELBW), very low birthweight (1001-1500 g, VLBW) and low birthweight (1501-2500g, 
LBW) [1]. 
 
 
Figure 1. Preterm birth rate in developed and developing countries. 
 
Despite advances in the identification of risk factors and mechanisms related to preterm 
labor, and the introduction of many public health and medical interventions, the PB rate 
has risen in most developed countries in recent decades [3,4]. Much of this increase can 
be explained by rising numbers of medically indicated PB as a consequence of maternal 
or fetal problems and by rising number of preterm multiple pregnancies associated with 
assisted reproductive technologies [5,6]. 
The highest mortality rates occur in VLBW infants [7]. The most common neurode-
velopmental complications in the early years of life of PB survivors are cerebral palsy 
(CP), mental retardation and sensory impairments (such as visual and auditory deficits). 
The definitions of the disabilities and their severity are not uniform, which makes inter-
pretation difficult, but about 25% of survivors have neurological disabilities [8,9]. Fur-
thermore, these complications are inversely related to GA. There is growing evidence 
that perinatal therapeutic strategies (i.e. antenatal steroids), careful delivery room 
management guaranteeing an adequate transitional phase, neonatal intensive care unit 
(NICU) treatments (respiratory support, surfactant) have resulted in a considerable 
decrease in perinatal mortality and morbidity. Nonetheless, there is an important role 
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for promotion of human milk. The latter is included in the indicators of clinical activity in 
the main neonatal networks (i.e. Vermont Oxford Network, VON) and a cut-off rate of 
>20% of HM at discharge has been internationally agreed [10].  
Breastfeeding in the NICUs 
The importance of nutrition in the early period of life is now well known: the term “pro-
gramming” has been proposed to emphasize that early nutrition should be considered 
both in terms of immediate nutritional needs and for long-lasting/life-long biological 
effects [11]. The mother her own milk is widely considered as the optimal feeding and 
also provides health benefits that are of vital importance for preterm infants in NICUs 
[10]. Feeding HM to preterm infants decreases rates of infection, necrotizing enterocol-
itis (NEC) and mortality, while improving neurocognitive and cardiovascular outcomes in 
the long term [10,12].  
A recent multicenter Italian study has reported the incidence of breastfeeding and 
use of HM among NICUs: at discharge 28% of infants were fed exclusively with HM 
(Table1). The proportion of infants not fed with HM varied from 6% to 82% across dif-
ferent centers [13].  
Table 1. Incidence of human milk at discharge from hospitals in Italy in relation to birth weight.  
 
Abbreviations: EBF, exclusive breastfeeding; EHM-ED, exclusive human milk including expressed and donated 
breast milk; HM, human milk. 
 
In this context the crucial role of health care workers, including pediatricians, to protect, 
promote and support breastfeeding, has to be emphasized. Health care workers should 
be trained in breastfeeding issues and counselling. Lack of feeding with breast milk is an 
important and costly problem for preterm infants that, if addressed successfully, has 
the potential to contribute to overcome inequalities in health [14]. 
Human Milk and biological aspects 
HM can be considered a species-specific biological "dynamic" system. Particular atten-
tion should be given to specific bioactive and immunomodulatory factors, such as gas-
trointestinal hormones, immunoglobulins, lactoferrin, lysozyme, oligosaccharides, nu-
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cleotides, growth factors, enzymes, antioxidants and cellular components. They not only 
ensure adequate host defense against infections, but also actively modulate the im-
mune response, modify the intestinal bacterial flora and are involved in the regulation 
of optimal newborn growth including that of the brain when compared to formula milks 
[15-17]. However, there is growing evidence that these compounds, per se, cannot be 
considered the only responsible of these crucial properties: to date, the hypothesis that 
other molecules of interest, namely “trophic factors” could also be involved in these 
developmental processes is therefore consistent [18-20] These latter include neuro-
oxidative stress biomarkers, neurotrophic and calcium binding proteins known to be 
involved in a cascade of events leading to brain, cardiac and vascular develop-
ment/damage [18-20]. The importance of these factors is also emphasized by their 
presence in HM, at up to 20 times or more higher concentrations than in other biologi-
cal fluids (i.e. cerebrospinal, CSF; blood; amniotic; urine) [19-22]. 
Selected biomarkers have a special role in human milk, such as: i) Neurotrophic fac-
tors — Activin A; ii) Calcium binding proteins — S100B; iii) Oxidative stress biomarkers 
— hemeoxygenase-1 (HO-1), iv) Vasoactive Agents – Adrenomedullin (AM). 
Pasteurized Donor Human Milk 
When mother's milk is unavailable or in short supply, donor milk (DM) represents a 
second best alternative. The American Academy of Pediatrics, in its most recent policy 
statement on breastfeeding, recommends that pasteurized DM should be used if moth-
er's own milk is unavailable or if its use is contraindicated [10]. To offer this opportunity 
to preterm infants, HM should be obtained from a HM bank (HMB). The number of 
HMBs is rapidly increasing worldwide. At present, in Europe, there are 186 HMBs, and 
new banks will be established with the support of the European Milk Bank Association 
[23]. In many countries, national policies to improve infant health outcomes consider 
DM obtained from an HMB to be a reasonable and effective tool in the delivery of 
health care to infants and children [24]. DM should be obtained from established HMBs 
that follow specific guidelines for screening, storage, and handling procedures to opti-
mize its composition while ensuring its safety for the recipient. Many countries now 
have their own HMB guidelines [25,26]. Pasteurization of the milk minimizes the risk of 
disease transmission, inactivating most of the viral and bacterial contaminants. In addi-
tion, donors are screened in a similar way as blood donors. No report has been pub-
lished showing transfer of diseases through pasteurized DM, although milk may contain 
microorganisms [27]. Nevertheless, HMBs, like blood banks, should be aware of the 
threat of emerging (milk transmissible) pathogens that are not included in contempo-
rary screening protocols. Currently, pasteurization, performed at 62.5 °C for 30 min 
(Holder Pasteurization, HoP), is recommended for this purpose in all international 
guidelines for establishment of HMBs [26].  
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Holder Pasteurization is necessary but partially seems to affect the nutritional and 
immunological properties of breast milk. Other alternative methods to improve the 
biological quality and safety of DHM are under investigation: high-temperature short-
term pasteurization (flash pasteurization, 72°C for 5–15 seconds) and its homemade 
low-tech variant for developing countries (flash-heat treatment), thermos-ultrasonic 
treatment, high-pressure processing, and Ohmic heat treatment. The data about safety 
for microbiological control are still scarce for most of these novel technologies, and 
consensus on processing conditions is necessary for non-thermal technologies, before 
any conclusions on the qualitative and nutritional advantages of these techniques can 
be drawn [28]. 
Refrigerated Human Milk 
Under some circumstances HM extraction and refrigerated storage may be necessary. 
The storage of refrigerated milk may also take place at hospitals (mainly in NICUs) or at 
home for milk to be donated to milk banks or for later use by the mother her own in-
fant. The maximum refrigeration time for human milk ranges between 24 hours and 8 
days, according the current advices on safe HM storage [29,30]. Such variability reflects 
the heterogeneity of the scientific sources, which is attributable to differences in study 
design and in methodological approach [31]. Depending on the length and on the type 
of storage, HM may lose some important nutritional and functional properties [32-35]. 
Recent studies have shown that human milk may be stored for 96h at 4°C without af-
fecting the overall milk integrity, as defined by bacterial growth, white cell count, pH, 
osmolality, and total protein count and protein profile. Moreover, Giribaldi et al. ob-
served that the refrigeration process did not affect the abundance of important nutri-
tional markers such as lysine, sIgA, lactoferrin and lysozyme content [36,37]. 
Neurotrophic factors — Activin A 
Activin A is a dimeric protein belonging to the transforming growth factor beta (TGF-
beta) superfamily. It is composed of two beta-A subunits exerting their biological activi-
ty through two different receptors and by the expression of the follistatin gene coding 
for the activin-binding protein follistatin, which inhibits its biological effects [38,39]. 
Activin A, its receptors, and binding proteins are widely distributed throughout the 
brain. Studies in experimental models and in humans strongly correlate enhanced Activ-
in A expression as a common response to acute neuronal damage of various origins. 
Hypoxic/ischemic injury, mechanical irritation, and chemical damage of brain evoke a 
strong up-regulation of Activin A [40]. Subsequent experimental studies have shown 
that Activin A has a beneficial role to neuronal recovery by activating different path-
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ways, Activin A exerts neuroprotective activities as well as it modulates cellular and 
tissue growth and differentiation [38]. On the basis of these findings it is reasonable to 
argue that Activin A for its involvement in embryogenesis and fetal development, could 
be detectable in biological fluids with a unique trophic effect such as breast milk. In this 
regard, Luisi et al. [39] investigated whether Activin A and follistatin as putative protec-
tive agents in central nervous system (CNS) and cardiac development were indeed pre-
sent in human milk. Immunohistochemistry showed positivity for Activin A and follistat-
in in human milk [19]. Of note, Activin A and follistatin concentrations were significantly 
higher than those detected in conventional biological fluids. The authors concluded that 
the presence of Activin A and follistatin in breast tissue is related with their hor-
mone/growth effect modulating growth and differentiation of mammary epithelial cells 
during lactation. Finally the Activin A and follistatin release in the neonatal circulation, 
suggests their involvement in the regulation of growth/function of various neonatal 
tissues including brain and cardiac tissues [41,42]. 
Calcium binding proteins — S100B 
The S100B protein (beta–beta dimer) is a member of a multigenic family of calcium-
binding proteins (S100 proteins) [43]. At least 21 proteins belong now to the S100 pro-
tein family, the members of which exhibit a pair of so-called EF-hand (i.e. helix-loop-
helix) calcium-binding motifs, which are able to change the conformation of the protein 
after binding to calcium. S100B is mainly concentrated in the CNS, where it is mainly 
located in the glial cells, astrocytes and Schwann cells, and more recently it has been 
shown in specific neuronal subpopulations [44]. The protein is present extracellularly, 
intracellularly, and in the cytosol; its half-life is about 1-h, and the 98% of the protein is 
eliminated by the kidney route [45]. S100B in CNS regulates several cellular functions 
(cell–cell communication, cell growth, cell structure, energy metabolism, contraction, 
and intracellular signal transduction). Elevated S100B levels have been found in differ-
ent biological fluids (i.e. CSF, blood, amniotic fluid, urine and saliva) in brain damaged 
fetuses and newborns [44,45]. Experimental and clinical data have shown that S100B 
behaves like a Janus face: at nanomolar (physiological) concentrations it acts as a cyto-
kine with a neurotrophic effect, while at micromolar concentrations it is neurotoxic and 
participates in a cascade of events leading to cell death and/or apoptosis [44]. On the 
basis of the present findings the detection of S100B in breast milk, offers additional 
support to the debate of the protein's involvement in fetal/neonatal brain develop-
ment. In particular, S100B concentrations in human milk were 200 times higher than in 
other biological fluids and higher than in other mammalian species (i.e. cow, goat, don-
key and sheep) [21,46]. More recently it has been reported that the protein's concen-
tration in milk formulae may be affected by industrial process procedures utilized for 
milk's preparation [47].  
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Oxidative stress biomarkers — HO-1 
HO-1 is a stress-inducibile rate-limiting enzyme that catalyzes the breakdown of pro-
oxidant heme into biliverdin, carbon monoxide (CO) and free iron, which can drive the 
synthesis of ferritin for iron sequestration [48]. Several studies have recognized HO-1 to 
be involved in several cytoprotective effects, due to its multiple catalytic by-products. 
The multifunctional roles of HO-1 have been shown in the vascular system, including 
vascular tone regulation, anti-smooth muscle proliferation and anti-endothelial apopto-
sis. More recently, it also has been shown to have a role in angiogenesis [49]. HO-1 is 
expressed in the human brain and is associated with brain tumors and neurodegenera-
tive diseases. Two genetically distinct isoenzymes have been identified: HO-2, which is 
constitutively expressed in various tissues and cells, and HO-1/HSP32 which is highly 
induced by many factors, including heavy metals, endotoxin, cytokines, heme, nitric 
oxide, hypoxia, and UV irradiation. It is interesting to note that induction of HO-1/HSP32 
expression by means of natural compounds contributes to protection against liver dam-
age in various experimental models [50,51]. Both isoforms are present in the endo-
plasmic reticulum, however, under certain conditions HO-1/HSP32 it has been shown to 
be able to translocate into other cellular compartments such as nuclei and mitochon-
dria [52,53]. Li Volti et al. [20] investigated the pattern of HO-1/HSP32 protein in human 
and milk-formula milks by HO-1/HSP32 assessment in milks together with a computa-
tional approach. The results showed the presence of HO-1/HSP32 in human milk, in 
particular, molecular modeling approach might explain a putative binding between HO-
1/HSP32 and his specific receptors (CD91) in the extracellular space playing a major role 
in the immune system regulation [20,54-56]. 
Vasoactive Agents – AM 
AM is a C-amidated peptide belonging to the calcitonin gene-related peptide family [57] 
first isolated from human pheochromocytoma by its capability to increase cyclic adeno-
sine monophosphate production [58]. AM and its mRNA have been found in many tis-
sues from different species. The main function of AM is vasodilatation [58], although 
other actions have been reported, including neuromodulation [59] and inhibition of 
apoptosis [60,61]. Expression of the AM gene is up-regulated by hypoxia [62,63] and 
inflammation [64], which are associated with neo-vascularization. Studies in animal 
models revealed that AM plays an important role in vascular formation in embryos [65-
67]. In the CNS, AM is generally localized in neurons and the endothelium [68], in par-
ticular in the hypothalamus [69] and in the caudate-putamen where it has been found 
in the neuronal nuclei [70]. This area is one of the most sensitive brain areas to hypoxic 
damage. In fact, AM is involved in response to hypoxia, at least in part by means of the 
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transcription of the Hypoxia-Inducible Factor-1, which enhances AM expression and 
stabilizes AM mRNA [71].  
AM has been implicated in the modulation of several physiological functions includ-
ing cardiovascular tone, central brain activity, bronchodilation, renal function, hormone 
secretion, cell growth-differentiation and immune response [72-81]. AM has been also 
assessed for evaluation of beneficial/side-effects of in-utero vasodilation therapeutic 
strategies in pregnancies complicated by fetal chronic hypoxia [74-76].  
Recent studies indicate that AM is also synthesized in the mammary gland and se-
creted in breast milk, although the data are discordant with respect to its concentra-
tion. On the other hand the presence of AM in HM and the variation in its concentration 
between the different milk maturation degrees suggest that AM may have an important 
role in the regulation of growth and maturation of the neonatal gastrointestinal tract 
[82-84]. 
Aim of the Thesis 
There is growing evidence that in HM and DM oxidative stress biomarkers, neurotrophic 
proteins and calcium binding proteins are involved in a cascade of events leading to 
brain, cardiac and vascular development/damage. On the basis of the aforementioned 
findings, the purpose of the present thesis was to investigate the effects of storage on 
HM constituents. The issues addressed are:  
i) the state of art of HoP effects on HM composition; 
ii) the changes in HM qualitative protein profile following HoP procedure;  
iii) the potential side-effects due to HP procedure on biomarkers such as Activin A, 
S100B, HO-1; 
iv) the potential side-effects due to prolonged refrigerated storage on AM. 
The present thesis to be defended at the University of Maastricht takes part to the Italy-
The Netherlands PhD Program under the auspices of the Italian Society of Neonatology 
(www.neonatologia.it), a research collaboration program between the Cesare Arrigo 
Paediatric Hospital (Alessandria, Italy) (www.ospedale.al.it), the University of Maastricht 
(The Netherlands) and the University of Utrecht (The Netherlands). 
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Abstract 
When a mother’s milk is unavailable, the best alternative is donor milk (DM). Milk deliv-
ered to Human Milk Banks should be pasteurized in order to inactivate the microbial 
agents that may be present. Currently, pasteurization, performed at 62.5 °C for 30 min 
(Holder Pasteurization, HoP), is recommended for this purpose in international guide-
lines. Several studies have been performed to investigate the effects of HoP on the 
properties of DM. The present paper has the aim of reviewing the published papers on 
this topic, and to provide a comparison of the reported variations of biologically-active 
DM components before and after HoP.  
This review was performed by searching the MEDLINE, EMBASE, CINHAL and 
Cochrane Library databases. Studies that clearly identified the HoP parameters and 
compared the same DM samples, before and after pasteurization, were focused on.  
A total of 44 articles satisfied the above criteria, and were therefore selected. The 
findings from the literature report variable results. A possible explanation for this may 
be the heterogeneity of the test protocols that were applied. Moreover, the present 
review spans more than five decades, and modern pasteurizers may be able to modify 
the degradation kinetics for heat-sensitive substances, compared to older ones. Overall, 
the data indicate that HoP affects several milk components, although it is difficult to 
quantify the degradation degree. However, clinical practices demonstrate that many 
beneficial properties of DM still persist after HoP. 
Key words: human milk; donor milk; holder pasteurization; Human Milk Banks. 
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Introduction 
Human milk (HM) is the gold standard for the feeding and nutrition of preterm and 
term newborns [1,2,3]. A mother’s own milk is the first choice for improving the short- 
and long-term outcomes for all neonates [1]. However, the benefits of HM are mediat-
ed by several specific bioactive and immunomodulatory factors, and HM can be consid-
ered a species-specific biological “dynamic” system [4]. When a mother’s own milk is 
unavailable or in short supply (a common occurrence in Neonatal Intensive Care Units), 
the World Health Organization and the American Academy of Pediatrics recommend 
the use of donor milk (DM) as the best alternative [1,3]. Milk delivered to Human Milk 
Banks (HMBs) should be pasteurized so as to inactivate viral and bacterial agents [5]. 
The ideal pasteurization process should consist of a phase of rapid heating, followed by 
a phase in which the temperature is maintained constant, and a final phase of rapid 
cooling.  
Currently, a pasteurization process at 62.5 °C for 30 min (the Holder pasteurization 
method, HoP) is recommended in all international guidelines for the constitution of 
HMBs [5,6]. Pasteurized milk is known to retain many beneficial and protective effects 
of HM. This method is thought to lead to a good compromise between the microbiolog-
ical safety and nutritional/biological quality of DM [7,8,9,10,11].Nonetheless, it is also 
well known that HoP affects some of the nutritional and biological properties of HM. 
Several studies have been performed to investigate the effects of Holder pasteurization 
on the nutritional and immunological properties of DM, but a comprehensive review 
and comparison of the related results is, to the best of the authors’ knowledge, not 
available in literature. Currently, the available data consist of reviews regarding the 
advantages of donor milk, but very few details are given on the effects of HoP on the 
nutrients of mother’s milk [12,13,14,15,16]. 
Thus, the present paper is aimed at reviewing the published papers, and at compar-
ing the results related to the effects of HoP on the biological and nutritive components 
of DM. 
Search Methodology 
The literature review was performed by conducting electronic searches of MEDLINE, 
EMBASE, CINHAL and the Cochrane Library. The electronic search used the following 
keywords and MeSH terms: (i) donor milk; (ii) banked milk; (iii) milk bank; (iv) milk bank-
ing; (v) (human milk OR donor milk) AND Holder pasteurization; (vi) (human milk OR 
donor milk) AND pasteurization; (vii) (human milk OR donor milk) AND storage; (viii) 
(human milk OR donor milk) AND heat treatment; (ix) (donor milk OR Holder pasteuriza-
tion) AND protein; (x) (donor milk OR Holder pasteurization) AND enzyme; (xi) (donor 
milk OR Holder pasteurization) AND lipid; (xii) (donor milk OR Holder pasteurization) 
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AND saccharide; (xiii) (donor milk OR Holder pasteurization) AND vitamin; (xiv) (donor 
milk OR Holder pasteurization) AND minerals; (xv) (donor milk OR Holder pasteurization) 
AND oxidative stress; (xvi) (donor milk OR Holder pasteurization) AND cytokine; (xvii) 
(donor milk OR Holder pasteurization) AND hormone; (xviii) (donor milk OR Holder pas-
teurization) AND growth factor; and (xix) (donor milk OR Holder pasteurization) AND 
immunoglobulin. No limits concerning the publication date were set. 
Considering differences between the research protocols published to date, we fo-
cused the review on studies with an experimental design that: 
- defined exactly the pasteurization method precisely (62.5–63 °C for 30 min); and 
- compared the same samples of HM before and after the heat treatment. 
In order to limit bias in the inclusion/exclusion process, the selection was made with the 
consensus of two authors (CP and MG). 
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Results 
A total of 58 articles were found from a combination of the searches, but only 44 ful-
filled all the inclusion criteria. Table 1 summarizes the technical details on the methodo-
logical aspects of the selected articles. Table 2, Table 3 and Table 4 provide an overview 
of the literature on the effects of HoP on different components of DM. 
Energy Content 
The first question that needs to be answered concerning the nutrition of all infants with 
pasteurized DM is: is this milk as nutritive as fresh HM? Only two studies have been 
found to have assessed the effects of HoP on the energy content of milk, with conflict-
ing results. Ley et al. [17] reported that the HM energy content was not modified by 
pasteurization, whereas García-Lara et al. [18] found that the energy content was de-
creased significantly. The two studies used different approaches to calculate the energy 
content; in the first case [17], a direct measurement was performed by means of bomb 
calorimetry, whereas in the second study the energy content was calculated on the 
basis of the fat, protein and lactose contents, as measured by means of infrared spec-
troscopy [18]. The discrepancy in the results may be due to statistical artifacts rather 
than to real differences, since the percent decrease measured in the two studies was 
similar. Overall, current evidence does not support the hypothesis of a relevant change 
in energy intake by feeding the infant with pasteurized rather than raw DM. 
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Nitrogenous Compounds 
Protein Content 
The composition of the HM protein fraction varies from mother to mother, and changes 
during lactation. The protein content of term milk is estimated to be approximately 0.9 
to 1.2 g/dL, while this value is higher for preterm milk [61].  
The true protein content of HM is often overestimated, due to its high proportion of 
non-protein nitrogen [62]. In a study by Vieirà et al. [19], the average DM protein con-
centration, as assessed by means of an infrared analyzer, was significantly reduced by 
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the HoP treatment, as was also found for colostrum [20]. Other studies, on the contra-
ry, did not observe any significant change in protein content [17,21,22,23], even when 
the total nitrogen content was measured indirectly [18]. In conclusion, the majority of 
the examined reports indicates that HoP does not affect the protein content of DM. A 
statistically significant reduction was only found in two studies, although one of the 
studies,involving mature milk [19], reported a very slight reduction (−3.9%), similar to 
that found in the studies that claimed no effect on total protein content. 
 
 
Immunoglobulins (Igs) 
The effect of HoP on the DM concentration of different classes of immunoglobulins has 
been investigated in several studies, the first being published in 1977 by Ford and col-
leagues [24]. 
IgAs and secretory IgAs (sIgAs) are the most extensively investigated classes, and al-
most all the published studies report a reduction following HoP. A significant reduction 
in IgAs following HoP was measured by means of Enzyme-Linked Immunosorbent Assays 
(ELISA) [25,26,27] and by means of Radial Immunodiffusion Assays (RIA) [28,29]. An IgA 
reduction was also reported in older studies [24,30], although no statistical significance 
was reached, perhaps due to weak experimental design. Ford et al. [24] analyzed a 
single pooled milk sample, while Evans et al. [30] used samples derived from overflow 
milk. The detrimental effect of HoP on IgAs was also confirmed on colostrum samples 
[20,31,32]. A reduction in protein bands recognized by means of anti-IgAs antibodies, 
although not quantified, was also reported [33]. Secretory IgAs, the dimeric forms of 
IgAs, were also found to have decreased following the pasteurization of DM [21,34,35], 
although not always significantly. 
The other Ig classes were investigated in a smaller number of studies, whose results 
are partially contrasting, due to the extremely low Ig concentrations, and subsequent 
difficult detectability in the milk samples. However, the majority of the studies found 
some degree of reduction. 
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IgM concentrations were measured in mature DM after pasteurization, and were 
found to be significantly decreased [26,28,29], or even completely degraded [24]. The 
low resistance of IgMs to pasteurization has also been confirmed more recently on 
colostrum [20,31,32]. The same behavior has also been observed for IgG concentrations 
in both milk [26,28,29,30] and in colostrum [20,31,32]. The specific thermal resistance 
of different IgGs subclasses was also detailed: IgG1 were not affected by HoP, while 
IgG4 were reduced, and IgG2 and IgG3 were undetectable in both fresh and pasteurized 
milk samples [31]. 
As an overall conclusion, the results from the previous reports clearly indicate that 
one of the main detrimental effects of HoP is a reduction in all classes of immunoglobu-
lins, probably due to the complex structure of these molecules. 
Lactoferrin and Lysozyme 
The immunoprotective protein constituents of HM, with bacteriostatic properties, in-
clude lysozyme and lactoferrin [62]. 
Lactoferrin is an iron-binding protein that reduces the availability of the free iron re-
quired by iron-dependent pathogens, and therefore is able to inhibit their growth. 
Moreover, it can disrupt the bacterial cell membrane by binding to the lipid-A portion of 
lipopolysaccharides on the bacterial cell surface [63]. Lactoferrin has been investigated 
in several studies, using different techniques (ELISA, RIA, monospecific antisera) 
[24,29,30,31,32], all of which report a reduction in its concentration, with a percentage 
ranging from 35% to 90%, but the reduction was only reported as significant by Christen 
et al. [35]. Additionally, a reduction in the lactoferrin-containing band, by means of a 
protein electrophoresis semi-quantitative method, was reported [33]. Since the bacteri-
cidal activity of lactoferrin is maintained by bactericidal peptides that form during its 
digestion, it is possible that part of the activity is still retained in pasteurized HM despite 
reduction of the protein [62]. One recent survey [64] conducted by means of non-
reducing protein electrophoresis, has reported that lactoferrin aggregation, rather than 
degradation, occurs following DM pasteurization with HoP. Whether this aggregation 
causes a decrease in lactoferrin bactericidal activity, is still not known. 
A similar pattern emerges for lysozyme, whose concentration has been found to be 
reduced after pasteurization in several studies, with a percentage ranging from 20% to 
85%. The biological activity of lysozyme was tested by Ford et al. [24], who did not find 
any significant difference. A significant reduction in lysozyme activity after HoP was 
found by other authors [25,36], even in colostrum [32]. It should be pointed out that, in 
those works, the lysozyme activity was always determined using a Micrococcus lyso-
deikticus-based turbidimetric assay, which measures to what extent bacterial growth is 
prevented by the addition of lysozyme-containing samples. Since DM is a complex mix-
ture of several anti-bacterial enzymes and factors, it is not possible to discriminate if the 
reduction is due only to a decrease in lysozyme concentration. 
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Other Enzymes 
Owing to their different responses to heating, enzymes and their activity are commonly 
considered as markers for assessment of thermal treatments. Some of these enzymes 
(such as lactoperoxidase and alkaline phosphatase) are considered technological mark-
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ers for pasteurization in bovine milk. Data on lactoperoxidase are scarce for HM, since 
its concentration is below the detection limit of commercial kits [24,32]. Alkaline phos-
phatase has also been found to be completely inactivated by HoP [21], as commonly 
found in bovine milk. 
Because of the compensatory function of several HM enzymes for nutrient digestion 
in newborns [65], some researchers have focused on the activity of lipase and amylase 
milk enzymes. A complete degradation (both in concentration and enzymatic activity) 
has been found for lipoprotein lipase and bile salt dependent lipase [21,33,37], while 
amylase activity was partly retained [37]. The clinical relevance of variations in the en-
zymatic activity of these proteins still has to be investigated. In particular, the hypothe-
sis of a reduction in nutrient absorption through feeding of pasteurized rather than raw 
HM, especially as far as lipid digestion is concerned, cannot be ruled out. 
Cytokines 
Although cytokines are immunomodulatory components, it appears that most of those 
found in HM are anti-inflammatory, thereby possibly lessening the effect of infections 
[62]. The effect of pasteurization on several cytokines has been evaluated in colostrum 
[31]. Interleukin (IL)1β, IL2, IL4, IL5, IL6, IL8, IL10, IL12, IL13, IL17, Interferon (IFN)-γ, the 
Tumor Necrosis Factor (TNF)-α and Monocyte Chemotactic Protein (MCP)-1 were not 
significantly affected by the process. Rather remarkably, IL7 increased significantly after 
pasteurization, perhaps due to its release from cellular and/or fat compartments into 
the aqueous fraction, while Macrophage Inflammatory Protein-1β (MIP-1β) was signifi-
cantly reduced [31]. IL2, IL4, IL5, IL12 and IL13 were unaffected even in pasteurized 
mature DM [38], while IL10 was decreased [38,39,40], as were IL1β [38], IFN-γ [39], IL6 
[39] and TNF-α [38,39]. A significant increase in IL8, following HoP in mature DM, was 
also found [38,39]. 
In short, different degrees of thermal resistance were found for different cytokines, 
and the biological relevance of this altered balance in specific situations still remains to 
be addressed. 
Growth Factors 
To date, only a few studies have evaluated the variation of growth factors (GF) in hu-
man milk after pasteurization, and each one has focused on one specific GF. Transform-
ing GF (TGF)-β2 was found to be stable in colostrum [31]. Epidermal GF (EGF) [40,41] 
and TGF-β1 [40] showed no difference before and after HoP. Heparin-Binding Epider-
mal-like GF (HB-EGF) was unaffected by heating, whereas Hepatocyte GF (HGF) was 
reduced to a great extent [38]. Insulin-like GF (IGF)-1 and 2, as well as IGF binding pro-
teins 2 and 3, were reduced to a variable extent by pasteurization [41]. Granulocyte-
Macrophage Colony-Stimulating Factor (GM-CSF) concentrations increased significantly 
after pasteurization, while the Granulocyte-Colony Stimulating Factor (GCSF) was not 
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detected in any sample, before or after HoP, either in colostrum [31], or in mature milk 
[38]. 
Once again, as in the case of cytokines, the low number of studies to date, and the 
relevant variability between different growth factors, does not allow any conclusion on 
the effect of HoP to be generalized. 
Amino Acids 
The DM amino acid composition was investigated in two studies, one [42] focusing only 
on sulfur amino acids (cysteine and methionine), and a few free amino acids. The au-
thors reported that no significant modification was caused by HoP, with the exception 
of an increase in free glutamine [42]. In another study [43], the amino acid profile of 
pre- and post-pasteurization DM was found to be significantly different for arginine and 
leucine, to increase following HoP, and to decrease for aspartate. Nevertheless, the 
biological relevance of these variations was reported to be low, since the differences, 
although significant, were small. 
The available lysine content, which is considered a nutritional marker, as lysine resi-
dues are targeted by proteases during digestion, was evaluated in two studies, with 
discordant results: Silvestre et al. [22] showed a 30% reduction (statistically significant) 
using a fluorimetric method, while Baro et al. [33] observed an increase in the concen-
tration of this amino acid, measured by means of o-phthaldialdehyde. In this case, the 
discordant results may partially be due to the different experimental designs of the two 
studies, one of which simulated HoP [22], and the other used a commercial Holder 
pasteurizer [33]. 
Hormones 
Insulin, adiponectin [17] and erythropoietin [40] concentrations were all reported to be 
decreased significantly after HoP, although the paucity of the reports does not allow 
any conclusion on the issue to be generalized. 
Vitamins 
The evidence on the effect of HoP on HM vitamins is contrasting. Folacin and vitamin 
B12 were evaluated in different studies with conflicting results, probably due to the 
significant instability of vitamins and to the variability between the study sampling and 
analysis methods of the studies. Ford et al. [24] found an important reduction in the 
capacity of DM to bind added vitamins after HoP, as measured by adding excess cyano-
cobalamin (vitamin B12 analog), while other studies [21,44] did not find any significant 
difference for vitamin B12 analyzed by means of a chemiluminescence immunoassay 
and a competitive protein binding assay. Stability of riboflavin, biotin, and the total 
pantothenic acid contents (vitamin B5) has also been observed [45]. A non-significant 
decrease was found for folacin (vitamin B9) after HoP [21,24,45]. Van Zoeren-Grobben 
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et al. on the other hand, found a 30% reduction in folacin as a consequence of HoP, and 
a significant 15% reduction in vitamin B6 [44]. 
While the vitamin C concentration was unambiguously reported to be reduced by 
HoP [44,46,47], fat-soluble vitamins showed different responses to pasteurization. Vit-
amin D was unaffected [44]. In some reports, vitamin A was found to be reduced 
[48,49], but other authors found it stable [23,44], while tocopherols (vitamin E) were 
found not to be affected in [44,46], but reduced in [39,47].To summarize, the available 
data seem to confirm a higher heat sensitivity for water soluble vitamins, and in particu-
lar for vitamin C, which is known to be highly susceptible to several technological treat-
ments, including freezing and refrigeration [66], while most of the studies seem to indi-
cate a higher retention of fat soluble vitamins (A, D, and partially E). 
Zinc 
Zinc levels have not resulted not to be significantly affected by HoP; however, a varia-
tion in the distribution of zinc was observed, with a significant increase in the fat frac-
tion and a decrease in whey, possibly as a result of the denaturation of zinc binding 
proteins, thereby indicating possible consequences on zinc bioavailability to the infant 
[23]. 
Lipids 
The total lipid content was evaluated in several studies: a significant reduction was 
found following HoP, using infrared analyzers [17,18,19], which, however, do not direct-
ly measure the fat content. Other authors have not found significant differences, when 
using different analysis techniques [23,37,50,51]. The total fatty acid profile was always 
found to be unaffected by pasteurization [37,39,43,47,50,52], with the exception of one 
study, which reported slight changes in the relative composition of medium-chain fatty 
acids (MCFAs) [38], and one of which reported a small decrease in 18:3 fatty acid [53]. 
Lepri et al. [51] found a more than two-fold free fatty acid content increase after pas-
teurization. A potential increase in the DM free fatty acid fraction following HoP, pro-
vided it does not cause off-flavors, may not be undesirable, as increased free fatty acids 
are known to be more readily absorbed in the digestive system, thus resulting in a pos-
sibly increased nutritive potential. 
Saccharides 
Several studies have evaluated the effect of HoP on lactose in mature milk and colos-
trum. In all cases, and using different analytical techniques, no significant difference was 
found before and after HoP [18,19,23,31,54]. The myoinositol levels were not affected 
by HoP either [31,54], while glucose was found to be increased [17], stable [31] and 
reduced [54], although all of the reported variations were low. 
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Glycosaminoglycans and oligosaccharides have recently been investigated in pre-
term milk, and no variation after the pasteurization process was observed [55,56]. 
These human milk glycans have been demonstrated to influence the health of new-
borns, since they possess specific biological properties, such as an anti-infective role, 
anti-oxidant functions and prebiotic effects [67]. 
In short, the evidence to date points toward the stability of DM saccharides during 
pasteurization by HoP, both as free molecules and as part of biologically active com-
pounds, such as glycosaminoglycans and oligosaccharides. 
Indicators of Thermal Treatment 
Lactulose, a disaccharide formed through the isomerization of lactose, and furosine, an 
intermediate of the Maillard reaction, have been searched for in DM, since they are 
used in the food industry to differentiate between different kinds of heat-treated bo-
vine milk, depending on the intensity of the heat treatment applied. Since HM has more 
than double the lactose content than bovine milk, lactulose formation has been found 
to be triggered more by pasteurization than is normally found for pasteurized bovine 
milk, in both milk [67] and colostrum [31]. Furosine was only found to have formed 
following pasteurization in colostrum samples [31], while it was not found in any milk 
sample [67]. Contador et al. [57] have very recently published a detailed analysis of 
volatile compounds in fresh and pasteurized HM, which supports the idea of some 
thermal-induced modification during HoP. The preservation of the original volatile com-
pounds in HM is important, since they can negatively affect its quality, and indicate that 
undesired reactions have taken place during the treatment (e.g., lipid oxidation, Mail-
lard reaction, etc.). A significant change in many volatiles was detected after HoP in DM; 
some of these volatiles (aldehydes, furans and pyrans) are undesired, and considered an 
index of thermal degradation. 
Oxidative Stress Markers 
The oxidative balance of raw and pasteurized HM was assessed by measuring both the 
accumulation of oxidants and the activity of oxidant scavengers. Malondialdehyde con-
centrations were not found to be significantly affected by HoP but, on the other hand, 
glutathione concentrations, glutathione peroxidase activity and Total Antioxidant Ca-
pacity were significantly reduced, thus indicating a decrease in the oxidative scavenging 
capacity of HM [58]. In a more recent assay [59], no change in malondialdehyde con-
centration, total antioxidant capacity (as measured by means of Oxygen Radical Absorb-
ance Capacity assay), or hexanal concentration has been found, thus indicating no lipid 
oxidation and no decrease in oxidant scavengers. 
Chapter 1 
46 
Organic Acids 
Only one study has assessed the l-lactate content of HM, following HoP, using a biosen-
sor based on an immobilized lactate oxidase enzyme. The results showed a significant 
increase, probably due to the release from interaction with other substances [51]. 
Recently Published Research 
One study has recently highlighted an increase in the nucleotide monophosphate con-
tent following pasteurization, measured by means of mass spectrometry. These com-
pounds are considered as immune-enhancers and seem to play a role as sleep-inducers, 
so their increase in HM may be a positive consequence of HoP [60]. Nevertheless, fur-
ther evidence is needed before any claim on the issue could be formulated. 
Discussion and Conclusions 
The present review shows a significant variability in the data reported in the scientific 
literature concerning the effects of HoP on the biological components of HM. A possible 
explanation for this variability may be the heterogeneity of the test protocols applied in 
the studies (e.g., in terms of sample origin, storage conditions or analysis methods). 
Another important source of variability is represented by the fact that the Holder pas-
teurization of donor milk is often simulated on small aliquots, rather than being per-
formed following HMB-implemented protocols. Moreover, modern pasteurizers require 
significantly less time for heating and cooling than older ones, thus changing the kinet-
ics of the thermal response for heat-sensible compounds. Additionally, it appears that 
some biochemical patterns were investigated more extensively than others, while some 
other milk components were not considered at all. 
The results of the review can be summarized as follows. Saccharides are not signifi-
cantly affected by the heat treatment, as either free molecules or as part of biologically 
active compounds. The total lipid content is preserved by HoP, as is its fatty acid com-
position. This finding is of paramount importance since it suggests that pasteurization is 
able to preserve both the nutritional and biological properties relevant to the develop-
ment of the central nervous system associated with some of these fatty acids. Consist-
ently, fat soluble vitamins also seem to be unaffected, while water soluble vitamins, and 
vitamin C in particular, are generally reported as significantly decreased. The results 
concerning specific biologically active molecules (such as cytokines and growth factors) 
remain uncertain, due to the vast number of different compounds analyzed in each 
study, and to the paucity of comparable results. 
Proteins are more significantly affected by HoP. In fact, specific proteins with signifi-
cant immunologic and anti-infective action (such as immunoglobulins and lactoferrin) 
are reduced by pasteurization. A substantial reduction in the enzymatic activity has also 
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been observed. The review thus confirms the main concerns about Holder pasteuriza-
tion of HM, and the need for future strategies to prevent and/or limit DM protein deg-
radation. The available data confirm that HoP affects several HM components to varia-
ble degrees, even though it is rather difficult to quantify the degradation level. None-
theless, clinical practices demonstrate that many beneficial properties of human milk 
remain, even after pasteurization. 
Future studies should be aimed at confirming the currently available data by investi-
gating more reproducible analytic settings, while avoiding the introduction of potential 
biases, in order to understand the real effects of pasteurization on mother’s milk. 
Moreover, further studies should be focused on new pasteurization techniques in order 
to improve the biological quality and safety of DM. 
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Abstract 
Background: The most widespread method for the treatment of donor milk is the Hold-
er pasteurization (HoP). The available literature data show that HoP may cause degrada-
tion of some bioactive components. The aim of this study was to determine the effect 
of HoP on the protein profile of human milk (HM) using a GeLC-MS method, a proteo-
mic approach and a promising technique able to offer a qualitative HM protein profile. 
Methods: HM samples were collected by standardized methods from 20 mothers carry-
ing both preterm and term newborns. A aliquot of each sample was immediately frozen 
at -80°C, whilst another one was Holder pasteurized and then frozen. All samples were 
then analyzed by GeLC-MS. The protein bands of interest were excised from the gel, 
digested with trypsin and identified by nano-HPLC-MS/MS analysis. 
Results: The protein profile before and after HoP showed qualitative differences only in 
6 samples out of 20, while in the remaining 14 no detectable differences were found. 
The differences interested only colostrums and transitional milk samples and regarded 
the decrease of the electrophoretic bands corresponding to alpha and beta-casein, 
tenascin, lactoferrin and immunoglobulin.  
Conclusions: In the majority of samples, HoP did not cause any modification, thereby 
preserving the biological activity of HM proteins.  
Key Words: Human milk; Donor Human Milk; Pasteurization Holder; GeLC-MS; Tenascin. 
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Introduction  
Human milk (HM) is considered the “gold standard” nutrition for feeding term and pre-
term newborns [1]. When mother’s own milk is not available or not sufficient, despite 
significant lactation support, Donor Human Milk (DM) is an important and the first al-
ternative, especially in high risk newborns admitted to Neonatal Intensive Care Units 
(NICU) [2,3]. The main benefit deriving from the use of DM versus formula milks, in 
preterm infant feeding, is the reduction in the incidence of necrotizing enterocolitis 
(NEC) as shown by several meta-analysis [4-7]. Moreover, an enhanced feeding toler-
ance has also been reported [3,8].  
The DM must be collected, processed and stored ensuring its microbiological safety 
maintaining at the same time the nutritional quality (NQ) [9]. NQ control of HM storage 
is complex as well as mandatory and pasteurization procedure is the main processing 
step to inactivate pathogenic microorganisms [2,10]. DM is typically pasteurized by 
Holder Pasteurization method (HoP) characterized by heating at 62.5 °C for 30 minutes. 
HoP is currently the requested procedure by the majority of Human Milk Banking Asso-
ciations (HMBA), being a temperature below 62,5°C considered not safe [2,10]. The 
impact of HoP on the biological quality of HM has been investigated and results are still 
controversial and matter of debate. The main explanations reside in the different pro-
cedures regarding samples collection, storage and treatment [11-13]. In this regard, 
data on the total protein count and specific proteins have been provided by using im-
mune-enzymatic techniques such as ELISA. Recently, GeLC-MS, a proteomic approach 
involving the separation of proteins in SDS-PAGE by one-dimensional electrophoresis 
(1DE) followed by identification by mass spectrometry (MS), has been suggested as a 
promising technique able to offer a qualitative HM protein profile [14]. Data on GeLC-
MS pattern in HM previously treated by HoP and later on stored at Human Milk Bank 
(HMB) are still lacking. 
Therefore, the purpose of the present study was to determine the effect of HoP on 
the protein profile of HM by using GeLC-MS analysis, under reducing and non-reducing 
conditions, in order to investigate the qualitative HM protein profile and the occurrence 
of protein aggregates, eventually formed after heat treatment. 
Methods 
Sample collection 
We conducted a pretest–test design, where HM samples acted as their own controls. 
Breast milk was collected, at different stage of maturation (colostrum: n=9; transitional 
milk: n=5; mature milk: n=6) according to Playford et al. [15], from 20 mothers delivered 
between 23 and 41 weeks of gestational age (GA). The study was approved by local 
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ethic committee and mother gave informed and signed consent to the study. Exclusion 
criteria were: maternal infections, tobacco smokers, drugs addiction and alcoholic; use 
of drugs or pharmacologically active substances; mothers who received blood transfu-
sions or blood products, or organ transplants; fetal malformations, chromosomal ab-
normalities, perinatal asphyxia and dystocia. HM samples were collected at two consec-
utive mornings, between 8-9 a.m., into disposable high density polyethylene sealed 
bottles (Flormed, Napoli, Italy) sterilized by using ethylene oxide. Milk expression was 
obtained by emptying one or two breasts with an electric breast pump (Medela Sym-
phony). From each container, 10 mL of HM were taken, divided into two fractions: the 
first was immediately frozen at -80°C; the second was pasteurized in HMB and frozen at 
-80°C. HoP was performed with a Sterifeed Pasteuriser by Medicare Colgate Ltd (Cul-
lompton, England), heating milk at 62.5°C for 30 minutes. The last HoP phase requires a 
rapid and precise cooling of milk samples to 10°C in approximately 20 minutes, by im-
mersion into cold water.  
Sample preparation and protein quantification 
Skimmed HM samples were obtained by centrifugation at 2000 x g for 30 min at 10°C, 
the pellet and the floating layer were discarded. Protein content was estimated accord-
ing to Bradford [16].  
GeLC-MS analysis and protein identification 
Skimmed milk samples were mixed with Laemmli buffer (2% w/v SDS, 10% Glycerol, 5% 
β-mercaptoethanol, 62 mM Tris-HCl pH 6.8), boiled for 5 min, and loaded on 10 x 8 cm 
vertical 12% polyacrylamide gels. For non-reducing conditions the Laemmli buffer did 
not contain β-mercaptoethanol and samples were not boiled. SDS-PAGE was performed 
at 10 mA per gel for 30 min and 30 mA per gel until the tracking dye front reached the 
bottom of the gel, at 10°C with a Mini Protean II Xi System (Bio-Rad). The running buffer 
was 25 mM Tris-HCl, 200 mM Glycine, 0.1% w/v SDS. The gels were stained overnight 
with Colloidal Coomassie brilliant blue G250 (Bio-Rad Laboratories) in accordance with 
Neuhoff et al. [17]. The Coomassie-stained gels were scanned using an Image Scanner III 
(GE Healthcare) at 300 dpi. The protein bands of interest were manually excised from 
1DE gels and in-gel digested with trypsin as described by Spertino et al. [18]. The pep-
tide mixtures were pooled and lyophilized in a SpeedVac for mass spectrometry analy-
sis.  
MS/MS analysis was performed using a QSTAR XL hybrid quadrupole–TOF instru-
ment (Applied Biosystems, Foster City, CA, USA) coupled with a LC Packings Ultimate 
3000 nano-flow LC system (Dionex, Amsterdam, The Netherlands), as described by Bona 
et al. [19]. Briefly, the QSTAR XL operated in positive mode and in information-
dependent acquisition (IDA) mode, the dynamic exclusion feature of the Analyst QS 1.1 
software (Applied Biosystems, Foster City, CA, USA) was enabled, with an exclusion 
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mass width of +/- 3 m/z for 60s. LC/MS–MS files obtained from each protein sample 
were merged into a single MASCOT generic format (mgf) file and searched against the 
NCBI non-redundant database; tolerance for precursor and fragment masses was 0.25 
Da. The proteins were identified in homology with significant ion scores (p<0.05). 
Statistical Analysis 
Clinical data are reported as the mean and SD. Protein content (mg/mL) are reported as 
median and interquartile ranges. Statistical analysis was performed using XLStat-Pro 
v.7.2.5 (Addinsoft, New York, USA). Results were compared between groups by Mann–
Whitney U-two sided test when the data did not follow a Gaussian distribution. A value 
of P<0.05 was considered significant. 
Results 
Demographic characteristics of milk donors 
The demographic characteristics of the milk donors are shown in Table 1. As expected, 
the incidence of delivery mode and the need of caesarean section were within the ref-
erence for our country. Gestational age and maternal age at birth were within reference 
curve for our national standards. All mothers showed normal clinical conditions. No 
overt neurological injury and/or infections were observed at the sampling time-points 
or at discharge from the hospital. 
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Table 1. Demographic characteristics of milk donors.  
Donor Mother’s ethnic 
group  
Age (yrs) Previous  
breastfeeding 
GA  
(wks) 
Delivery 
Mode 
Milk maturity  
degree 
Spontaneous 
Pregnancy 
1 Caucasian 38 Yes 28 CS Mature Yes 
2 Caucasian 31 Yes 25 V Transitional Yes 
3 Caucasian 38 Yes 35 C Transitional Yes 
4 Caucasian 35 Yes 31 CS Mature Yes 
5 Caucasian 35 No 23 CS Mature No 
6 Caucasian 39 No 35 V Transitional Yes 
7 Caucasian 37 No 27 V Transitional Yes 
8 Caucasian 25 No 29 CS Mature Yes 
9 Caucasian 31 Yes 32 CS Mature Yes 
10 Caucasian 33 No 33 CS Transitional Yes 
11 Caucasian 30 No 31 CS Mature No 
12 Caucasian 22 No 38 V Colostrum Yes 
13 Other 33 Yes 40 V Colostrum Yes 
14 Caucasian 28 No 38 V Colostrum Yes 
15 Caucasian 34 No 39 CS Colostrum Yes 
16 Caucasian 40 Yes 38 V Colostrum Yes 
17 Caucasian 39 Yes 37 V Colostrum Yes 
18 Caucasian 36 No 37 V Colostrum Yes 
19 Caucasian 37 Yes 37 V Colostrum Yes 
20 Caucasian 33 No 41 V Colostrum Yes 
Abbreviations. Years (yrs); weeks (wks); caesarean section (CS); vaginal (V).  
Total protein content determination  
The data of protein content are reported in No-Holder pasteurized (NO-HoP) and Hold-
er pasteurized (HoP) groups in Table 2 and in Table 3. Both in NO-HoP than in HoP 
groups no significant differences (P>0.05, for all) have been found in total protein con-
tent, also after correction for milk maturity degree (Table 2).  
Table 2. The median of protein content in human milk samples before (No-HoP) and after Holder pasteuriza-
tion (HoP). Data are given in median and interquartile ranges. 
Parameters No-HoP HoP 
 Median 25% 75% Median 25% 75% 
All milk samples (n=20) 14.49 10.28 17.22 11.96 10.21 15.65 
Colostrum (n=9) 14.58 13.69 20.32 12.22 11.32 17.72 
Transitional (n=5) 14.89 10.42 16.76 14.50 10.63 15.52 
Mature (n=6) 11.30 8.91 16.71 9.96 8.35 12.00 
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Table 3. Protein content (mg/ml) in human milk samples before (No-HoP) and after Holder pasteurization 
(HoP). 
Sample No- HoP HoP 
1 12,99 10,16 
2 9,99 10,76 
3 17,85 14,50 
4 8,92 12,00 
5 8,02 7,62 
6 14,89 15,39 
7 10,57 10,27 
8 16,71 8,36 
9 29,10 30,13 
10 16,40 15,92 
11 9,63 9,77 
12 29,42 21,87 
13 13,09 7,82 
14 14,59 11,11 
15 13,89 12,23 
16 14,41 11,92 
17 16,29 15,14 
18 28,05 31,86 
19 9,83 11,40 
20 17,74 16,34 
Proteomic analysis and protein identification 
The separation of proteins using 1DE permits to visualize the various protein species in 
a biological sample; Figure 1 shows electrophoretic separation of milk’s proteins, under 
reducing and non-reducing conditions. 
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Six out of 20 samples, corresponding to colostrum (n=5) and transitional milk (n=1), 
showed a reduction of band intensity whilst no changes were observed in the mature 
milk samples. There were no differences in the six samples after correction for delivery 
mode and/or gestational age at birth. Reduction of intensity was observed in three 
regions: <20kDA; 25-30kDa; >250kDa. Concerning the bands in the region between 25 
and 30 kDa, the distribution of aggregates between protein fragments was altered by 
pasteurization in five milk samples, individually or in association with other modifica-
tions.  
The proteins identified by MS in the different regions (Figure 2), are shown in Table 4. 
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Table 4: List of proteins identified from bands showing changes after Holder pasteurization. 
Band 
no. 
Protein ID AC number  
(gi NCBI) 
Theoretical 
Mr (kDa) 
MASCOT 
score 
Sequence 
coverage  
(%) 
MS/MS sequencing 
1 TNC variant 
protein 
68533131 244.2 1177 15% R.LEELENLVSSLR.E 
      K.FTTDLDSPR.D  
      R.ELEPGVEYFIR.V 
      R.VFAILENKK.S 
      R.VATYLPAPEGLK.F 
      R.QTGLAPGQEYEISLHIVK.N 
      R.LDAPSQIEVK.D 
      K.ETFTTGLDAPR.N 
      R.VSQTDNSITLEWR.N 
      K.TTLTGLRPGTEYGIGVSAVK.E 
      K.EDKESNPATINAATELDTPK.D 
      K.ESNPATINAATELDTPK.D 
      R.GLEPGQEYNVLLTAEK.G 
      K.AATPYTVSIYGVIQGYR.T 
      R.AVDIPGLEAATPYR.V 
      R.TPVLSAEASTAK.E 
      K.QSEPLEITLLAPER.T 
      R.EATEYEIELYGISK.G 
      R.APTAQVESFR.I 
      K.FTTDLDSPR.D 
      R.DLTATEVQSETALLTWRPPR.A 
      K.EVIVGPDTTSYSLADLSPSTHYTAK.I 
      K.IQALNGPLR.S 
      R.EEFWLGLDNLNK.I 
      K.ITAQGQYELR.V 
      R.DHGETAFAVYDKFSVGDAK.T 
2 Beta-casein  288098  25.2 63 12% K.SPTIPFFDPQIPK.L  
      K.VLPIPQQVVPYPQR.A  
3 Beta-casein  288098  25.2 65 12% K.SPTIPFFDPQIPK.L  
      K.VLPIPQQVVPYPQR.A  
4 Lactotransferrin 16198359  78.3 333 8% R.YYGYTGAFR.C  
      R.THYYAVAVVK.K  
      R.SDTSLTWNSVK.G 
      R.CLAENAGDVAFVK.D  
      R.RSDTSLTWNSVK.G  
      K.LRPVAAEVYGTER.Q  
 Immunoglobulin 
kappa light 
chain VLJ region  
21669409 29.8 118 17% R.TVAAPSVFIFPPSDEQLK.S 
      K.DSTYSLSSTLTLSK.A 
      K.VYACEVTHQGLSSPVTK.S 
 Beta-casein  288098  25.2 106 28% K.SPTIPFFDPQIPK.L  
      K.VLPIPQQVVPYPQR.A  
      R.AVPVQALLLNQELLLNPTHQIYPVT
QPLAPVHNPISV.-  
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Table 4: Continued 
Band 
no. 
Protein ID AC number  
(gi NCBI) 
Theoretica
l Mr (kDa) 
MASCOT 
score 
Sequence 
coverage  
(%) 
MS/MS sequencing 
4 Lactotransfe
rrin 
16198359  78.3 333 8% R.YYGYTGAFR.C  
 Immunoglob
ulin lambda 
light chain  
33700 25.2 77 20% R.SYSCQVTHEGSTVEK.T  
      K.YAASSYLSLTPEQWK.S  
      K.AAPSVTLFPPSSEELQANK.A  
5 Immunoglob
ulin kappa 
light chain 
VLJ region 
21669357 29.5 381 34% K.LLIYWASTR.E  
      K.DSTYSLSSTLTLSK.A 
      K.SGTASVVCLLNNFYPR.E 
      K.LYACEVTHQGLSSPVTK.S  
      R.TVAAPSVFIFPPSDEQLK.S  
      K.VDNALQSGNSQESVTEQDSKDST
YSLSSTLTLSK.A 
 Alpha S1-
casein  
1359714  20.7 192 19% R.LQNPSESSEPIPLESR.E  
      R.LNEYNQLQLQAAHAQEQIR.R 
 Immunoglob
ulin lambda 
light chain  
33700 25.2 139 14% K.YAASSYLSLTPEQWK.S  
      K.AAPSVTLFPPSSEELQANK.A  
 Beta-casein 
precursor  
4503087  25.4 115 11% K.SPTIPFFDPQIPK.L  
      K.VLPIPQQVVPYPQR.A  
6 Beta-casein  288098  25.2 49 12% K.SPTIPFFDPQIPK.L  
      K.VLPIPQQVVPYPQR.A  
7 Alpha S1-
casein 
1359714  20.7 56 10% R.LNEYNQLQLQAAHAQEQIR.R 
 Beta-casein  288098  25.2 50 12% K.SPTIPFFDPQIPK.L  
      K.VLPIPQQVVPYPQR.A 
       
8 Beta-casein  288098  25.2 38 12% K.SPTIPFFDPQIPK.L  
      K.VLPIPQQVVPYPQR.A  
9 Beta-casein  288098  25.2 81 12% K.SPTIPFFDPQIPK.L  
      K.VLPIPQQVVPYPQR.A  
 tenascin 37227  240.6 70 1% R.LEELENLVSSLR.E  
 alpha S1-
casein 
1359714  20.7 65 10% R.LNEYNQLQLQAAHAQEQIR.R  
10 Lactoferrin 186833  78.3 203 3% R.THYYAVAVVK.K  
      K.LADFALLCLDGK.R  
      K.NLLFNDNTECLAR.L  
 Beta-casein  288098  25.2 38 6% K.VLPIPQQVVPYPQR.A 
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Discussion 
When mother’s own milk is not sufficient, donor milk is the first best choice for feeding 
term and preterm newborns, due to its well-recognized nutritional advantages with 
respect to formula milk [4-8]. DM should be obtained from established HMBs that fol-
low specific guidelines for screening, storage, and handling procedures to optimize its 
composition while ensuring its safety for the recipient. [2,10] All the milk arriving to the 
Human Milk Bank must be pasteurized. The ideal pasteurization process should consist 
of a phase of rapid heating followed by a phase of constant maintenance of the tem-
perature and a final phase of rapid cooling. Pasteurization of the milk minimizes the risk 
of disease transmission via HM, inactivating most of the viral and bacterial contami-
nants. In addition, donors are screened in a similar way as for blood donation. No report 
has been published showing transfer of diseases through pasteurized DM, although milk 
may contain microorganisms. [2,10]. Currently Holder Pasteurization (62.5°C for 30 
minutes) is the gold standard for milk processing in Human Milk Banks and is recom-
mended by several guidelines as the optimal compromise between quality and microbi-
ological safety [2,10]. Several studies have already been performed to evaluate the 
effects of pasteurization on mother’s milk macronutrients; the related results are often 
discordant, especially concerning proteins [8,20-22].  
Our study observed a non-significant reduction of the total protein count following 
HoP of milk samples. This result is in line with the available literature: several studies 
reached similar conclusions using different analytical methods [20,21]. Only Vieira et al. 
in 2011 found that there was a significant reduction in the mean protein concentra-
tions, between the raw and post-pasteurization samples (reduction of 3.9%). However, 
these samples were only analyzed with the use of a FT-IR infrared analyzer [22].  
The original contribution of our study consists of the use of a semi-quantitative ana-
lytical method, GeLC-MS analysis. This technique allows to evaluate the protein profile 
of human milk, which is constituted by a complex array of biologically active proteins. 
Each sample was tested and compared under reducing and nonreducing conditions, to 
highlight the possible presence of protein-complexes due to disulfide bond formation in 
the pasteurization step. However this method is not able to evaluate the protein chang-
es associated whit interaction between proteins and sugars, or proteins and lipid due to 
thermic treatments. No differences were observed between the electrophoretic profile 
of the same sample under reducing and nonreducing conditions, except for the region 
of high molecular weight, probably corresponding to the formation of high-mass com-
plexes which do not run in the gel. Over 75 kDa, we observed more numerous and well 
separated bands under reducing conditions. The peculiarity in our data consists of the 
observation that no variation is present in 14 out of 20 samples (previous studies have 
detected a variation in all samples). It is also noteworthy that amongst the 6 samples 
presenting a modification in the protein levels, 5 derived from colostrum milk and only 
1 from transitional milk. This finding is relevant from a clinical practice standpoint, since 
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donor milk usually consists of mature milk (which, according to our data, did not show 
any variation). Each band showing a variation was then identified with the correspond-
ing protein(s). The bands of greatest interest are the ones of medium molecular weight 
(25-30 kDa) since they contain beta casein, alpha-casein, lactoferrin fragments and 
immunoglobulin light chains (Igκ and Igλ); the other band of interest (250 kDa) was 
identified as tenascin. 
Tenascin is a homohexameric disulfide-linked glycoprotein and its expression de-
creases with lactation. This protein was investigated in recent studies for its antimicro-
bial properties in milk and Fouda et al. have hypothesized its ability to neutralize the 
HIV-1 virus via binding to the chemokine receptor site [25]. Tenascin has never been 
evaluated previously in human milk after pasteurization and we observed a reduction 
only in reduced samples of colostrum. 
Beta-casein and alpha-casein are two important proteins of human milk. Only one 
previous study has investigated the effect of Holder pasteurization on these proteins 
using an electrophoretic analysis method and has shown a slight decrease in a single 
pooled sample [14].  
IgA antibodies in breast milk provide passive immunity and sufficient protection 
against infections to neonates and preterm infants [24]. Lactoferrin is a bioactive pro-
tein that serves as an immunomodulatory factor [24]. Several studies revealed a num-
ber of functions of these molecules: i) IgA has specific antigen-targeted anti-infective 
action; ii) lactoferrin plays important roles in immunomodulation, iron chelation and 
antimicrobial action, and exhibits the anti-adhesive and trophic properties necessary for 
intestinal growth [24-25]. Overall, regarding lactoferrin and IgA, our study is partially in 
agreement with the results reported in the literature, in which a decrease was found in 
all samples tested, in contrast to our findings. There might be two reasons for these 
differences: i) we did not use pooled milk (as done in several previous studies) but we 
have analyzed all milk samples individually; furthermore the same samples have been 
analyzed before and after pasteurization; ii) we have utilized a GeLC-MS analysis (semi-
quantitative technique), instead of an immunohistochemical analytical techniques like 
the ELISA test. Additionally, there is a significant variability in previous studies concern-
ing the retention of these proteins after HoP, which can be ascribed not only to hetero-
geneity in methods of human milk collection but also to treatment and storage before 
and after HoP [11-13].  
In conclusion, donor milk needs a heat treatment for a safety storage. Holder Pas-
teurization is the method recommended by all international guidelines for the constitu-
tions of Human Milk Banks. Our data are in agreement with literature showing a small 
decrease in the total protein content of human milk after HoP. Nonetheless, samples 
obtained from different donors reacted differently to heat treatment, even if processed 
and stored using the same conditions: in particular, 30% of the samples showed some 
differences in the protein profile after HoP, whereas 70% of the samples showed no 
detectable differences. The detectable effects on the protein profile were mainly in 
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colostrum samples; this variation is quite interesting from a clinical standpoint, since 
donor milk is mostly constituted by mature milk. The reasons for this apparent variabil-
ity is not clear and would deserve further investigation. In this setting, future studies 
should be designed to investigate whether these differences are also confirmed by 
other techniques able to assess the protein changes due to thermic treatments includ-
ing the interaction between proteins and sugars, or proteins and lipid with possible 
toxic derivatives. 
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Abstract 
Introduction: There is evidence that mother’s own milk is the best nutrient in terms of 
multiorgan protection and infection prevention. However, when maternal milk is scarce, 
the solution can be represented by donor milk (DM), which requires specific storage 
procedures such as Holder Pasteurization (HoP). HoP is not free from side effects since 
it is widely known that it causes qualitative/quantitative changes in milk composition, 
particularly in the protein content. Therefore, the aim of this study is to investigate the 
effects of HoP on Activin A, a neurobiomarker known to play an important role in the 
development and protection of the central nervous system. 
Methods: In 24 mothers who delivered preterm (n = 12) and term (n = 12) healthy new-
borns, we conducted a pretest/test study where the milk donors acted as their own 
controls. Each sample was divided into two parts: the first was frozen at -80°C (Group 
1); the second was Holder-pasteurized before freezing at -80°C (Group 2). Activin A was 
quantified using an ELISA test. 
Results: Activin A was detected in all samples. There were no significant differences (p > 
0.05) between the two groups, also when the analysis was stratified for gestational age 
at delivery and milk maturation degree (p > 0.05, for both). 
Conclusion: The present findings on the absence of any side effects of HoP on the milk 
concentration of Activin A offer additional support to the efficacy of HoP in DM storage. 
Our data open up to further investigations on neurobiomarkers’ assessment in human 
milk and their preanalytical stability according to storage procedures. 
Key Words: Human milk; Donor Milk; Pasteurization Holder; Activin A; Central Nervous 
System 
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Introduction 
There is ample evidence that breastfeeding is the most recommended way of promot-
ing infant growth and development and that mother’s own milk is the best nutrient in 
terms of multi-organ protection and infection prevention [1,2]. The explanation for this 
resides in the “biochemical communication” between mother and child which, thanks 
to human milk, allows a continuous exchange of growth factors, cytokines and hor-
mones [3,4]. Cytokines (neuro-oxidative stress biomarkers, neurotrophic and calcium 
binding proteins) appear to be of particular interest for their involvement in a cascade 
of events leading to the correct development of the central nervous system (CNS) and 
cardiovascular system [5]. Although breastfeeding is considered a “life-saving” proce-
dure, this practice is not free from issues. The main one consists of the poor availability 
of maternal milk, particularly in high-risk infants admitted to neonatal intensive care 
units (NICU). In these cases, the solution can be represented by human donor milk 
(DM), which nonetheless requires safe procedures for milk storage and conservation 
[2,6,7]. In this regard, DM can be stored at Human Milk Banks (HMB) after Holder pas-
teurization (HoP) (62.5°C for 30 minutes) [7]. Advantages and disadvantages associated 
to this procedure have been widely discussed in Literature. The advantages consist of 
improved protection against infections and contaminations, whilst disadvantages are 
represented by qualitative/quantitative changes in milk composition [6,8,9]. This may 
especially refer to neurobiomarkers (NB), such as Activin A, known to play a relevant 
role in brain development and protection [10].  
Activin A is a dimeric protein belonging to the transforming growth factor beta (TGF-
beta) superfamily and its receptors are widely distributed in the brain [11]. Studies in 
humans and animal model showed that Activin A can play a trophic and neuroprotective 
role on the CNS [12]. In this regard, increased Activin A levels in different biological 
fluids have been found in infants presenting perinatal asphyxia, prematurity and intra-
ventricular hemorrhage [13-15]. There is evidence that this protein also exerts a neuro-
protective activity (i.e., neuronal recovery, modulation in cellular and tissue growth and 
differentiation)[16-18]. Activin A has been also detected in human milk supporting its 
role as a growth factor [19]. Of note, data regarding the variation of Activin A levels in 
DM after HoP pasteurization are lacking.  
Therefore, the purpose of the present study was to investigate the effects of HoP on 
Activin A concentration in healthy DM mothers.  
Materials and Methods 
The study protocol was approved by the local Ethic Committee of the Italian Association 
of Human Milk Donor Banks (AIBLUD). Mothers admitted into the study gave signed and 
informed consent. We conducted a pre-test/test study, where the milk donors acted as 
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their own controls. Milk samples (colostrum: n=12; transition: n=12; mature: n=12, 
respectively) [20] were collected from 24 healthy mothers having delivered at term and 
preterm of gestational age (GA) (GA> 37 weeks and GA< 37 weeks respectively) and 
coming from consecutive singleton physiological pregnancies (Table 1) [21]. 
We excluded mothers affected by any CNS illness; pregnancies complicated by ges-
tational diabetes and hypertension; multiple pregnancies; fetuses with any malfor-
mation and/or chromosomal abnormalities; systemic infection; intrauterine growth 
retardation, or cardiac or hemolytic disease, malnutrition and maternal allergy. Stand-
ard exclusion criteria for human milk donation set forth by AIBLUD guidelines were also 
applied [7].  
Collection and pasteurization of human milk 
Fresh milk samples were collected at the same time (9-10 a.m.) into sterile, disposable, 
high-density polyethylene sealed bottles (Flormed, Naples, Italy). The milk was collected 
by means of an electric breast pump (Medela Symphony, Baar, Switzerland) with stand-
ard extraction methods. According to current guidelines and in order to collect full 
pumping samples, the extraction session was stopped 2 minutes after the outflow of 
the last drops of milk [7,22]. From the total amount of milk of each mother, a sample of 
10 mL of milk was collected and then subdivided into two aliquots. The first was imme-
diately frozen at -80°C (NO-HoP), while the second aliquot was pasteurized and then 
frozen at -80°C (HoP). HoP was performed with a Sterifeed pasteurizer (Medicare Col-
gate Ltd, Cullompton, UK) heating milk samples at 62,5° C for 30 minutes, then cooling 
to 10°C in approximately 20 minutes by immersion into cold water. The time interval 
between freezing and the analysis of the milk samples was less than 6 months (median 
4 months).  
Activin A measurements 
Samples were immediately stored at -80°C until analysis. Activin A levels were deter-
mined using a specific ELISA test (ELH-ActivinA-1 Human Activin A ELISA) according to 
the manufacturer's instructions (RayBiotech, Inc.; USA). Investigators who performed 
the laboratory tests were blind to storage modalities. The analysis was performed with-
in 2 hours from samples thawing. The assay detection limit is 15.00 pg/ml, the coeffi-
cient of variability intra-assay was ≤ 5.0%, and the inter-assay ≤ 10%, respectively. The 
assay is specific for Activin A, having been tested by the manufacturer for lack of cross-
reactivity with other proteins of the Activin family.  
Statistical Analysis 
Demographic characteristics of maternal and neonatal outcomes were reported as 
mean ± SD. Activin A concentrations were expressed as median and interquartile rang-
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es. Statistical analysis was performed by using two-tiled paired t-test and by Mann–
Whitney two-sided U-test when data did not follow a Gaussian distribution. Comparison 
between groups was performed by using ANOVA one-way test for multiple compari-
sons. A P<0.05 was considered significant. 
Results 
Maternal and perinatal characteristics of milk donors are reported in Table 1. As ex-
pected, all mothers were in normal clinical conditions. No overt neurological injury 
and/or infections were observed at the sampling time points or at discharge from the 
hospital. 
Table 1. Demographic characteristics of milk donors and infant.  
Parameters n=24 
Mean (±SD) maternal age, years  35 (± 3)  
Parity 1 n. (total) 13 (24) 
Mode of delivery, n.  
Caesarean 
Vaginal 
 
6  
18  
Mean (±SD) gestational age, weeks 36 (± 5) 
Mean (±SD) birth weight, g 2950 (± 1120) 
Gender male (female) 11 (13) 
 
Activin A protein was detectable in all the measured milk samples, either in term and 
preterm milk samples, before and after HoP. Activin A concentrations were lower in 
preterm milk respect term milk samples but this difference was not significant (P>0.05). 
Table 2 Activin A concentrations (pg/mL) in human milk samples before and after HoP. Data are expressed as 
median and interquartile ranges.  
Activin A Before HoP After HoP P 
 Median 25 centile 75 centile Median 25 centile 75 centile  
Total milk samples  3733,5 1768,5 9379,7 3083,5 1467,2 5698,5 0.22 
Colostrum  5266,0 2283,5 9291,0 3221,0 1878,5 3806,0 0.14 
Transitional milk  4938,5 1948,5 11718,5 3936,0 1453,5 8598,0 0.79 
Mature milk  3198,5 1708,5 9078,5 2233,05 1508,5 5638,5 0.77 
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As shown in Figure 1, no significant differences (P>0.05, for both) in Activin A levels 
were observed in all milk samples before HoP (median: 3733,5pg/mL; 25° centile: 
1768,5 pg/mL and 75° centile: 9379,75 pg/mL) and after HoP (median: 3083,5 pg/mL; 
25° centile: 1467,2 pg/mL and 75° centile: 5698,5pg/mL) process.  
 
Figure 1. Activin A concentrations (pg/mL) in total human milk samples before and after HoP procedure. The 
lower and upper bars represent the 5th and 95th centiles, respectively; interquartile range is indicated by the 
box and median value is represented by the horizontal line in the box. No significant differences have been 
found between studied groups (P>0,05). 
 
No significant differences (P>0.05) were found between groups when Activin A concen-
trations were compared in sub-groups for gestational age (i.e., term vs preterm) (Figure 
2). Furthermore, Activin A levels did not differ (P>0.05) in both groups when sub-
grouped based on the degree of milk maturation. 
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Figure 2. Activin A concentrations (pg/mL) in human milk samples before (pre) and after (post) HoP procedure 
in term (T) and preterm (PT) infants. The lower and upper bars represent the 5th and 95th centiles, respective-
ly; interquartile range is indicated by the box and median value is represented by the horizontal line in the 
box. No significant differences have been found among studied groups (P>0,05). 
Discussion 
Current guidelines recommend Holder Pasteurization as the best thermal treatment for 
storage of donor milk in Human Milk Banks since it guarantees protection against infections 
and contaminations [6-8]. On the other side, there is still no conclusive consensus whether 
this procedure may affect the biological quality of the nutrients in donor milk [6,9]. 
The present study provides evidences that HoP does not modify milk concentrations 
of a neurotrophic protein, namely, Activin A. Indeed, no changes in protein’ concentra-
tions attributable to HoP procedure were observed throughout the various lactation 
phases and in correlation with gestational age. Results are, in part, in agreement with a 
previous observation by Luisi et al. who detected Activin A in colostrum, transition and 
mature milks of mothers having delivered at term of gestational age [19]. The discrep-
ancy resides in the lack of any differences, observed in our series, among Activin A lev-
els in mature milk versus transition and colostrum milks. The fact can be of relevance 
bearing in mind the changes in milk composition and properties throughout its stages of 
maturation [23]. Anyway, the finding of no significant changes in Activin A levels herein 
reported warrants further consideration. In addition, the present study identified for 
the first time dimeric Activin A in milk collected from lactating healthy women having 
delivered preterm. We observed a lower Activin A levels in this mothers groups but no 
significant differences were found respect the milk samples of mother having delivered 
at term of gestational age.  
In particular, Activin A has been shown to: i) exert a neurotrophic role being involved 
in growth and differentiations of many CNS target cell-types [5,10]; ii) play, in vitro and 
in vivo, a beneficial role in recovery and survival of neurogenic cell lines and retinal 
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neurons decreasing ischemic brain injury [24-27]; iii) exert CNS protection from antide-
pressant treatment side-effects [28,29]; iv) be a trustable predictor, when measured in 
different biological fluids (amniotic, arterial cord blood, urine and cerebrospinal) of 
cerebral bleeding and damage in fetuses and newborns [5,16]. Altogether, it is reasona-
ble to conclude that HoP per se guarantees an unaltered Activin A intake to the new-
born and its neurotrophic properties offering additional support to the unique role of 
human milk. The fact is of relevance taking into account that artificial milk industrial 
preparation procedures have been shown to affect in a significant manner milk compo-
sition and properties [30].  
Among the different Activin A functions (to date still matter of investigation and de-
bate) it has been shown that the protein participates in a cascade of events leading to 
breast tissue differentiation [31,32]. Nonetheless, Activin A pro- and anti-inflammatory 
effects on human tissues increasing cytokine production from monocytes in normal 
humans peripheral blood mononuclear cells and regulating T cell development have 
been also reported [32-34]. The issue highlights the importance of DM administration in 
the immune protection of preterm infants.  
Finally, there is also evidence that the protective role of Activin A is also extended to 
the heart tissue. In particular, it has been reported that the protein can participate in a 
cascade of events promoting tissue protection and regeneration in patients undergone 
to ischemia/reperfusion injury [35-37]. Therefore, on the basis of the aforementioned 
findings, it is reasonable to argue that Activin A is involved not only in the CNS devel-
opment but can be considered a multi-organ trophic factor taking part to the embryo-
genesis. The fact that is detectable in a biological fluid at unique trophic effect such as 
breast milk corroborates the aforementioned hypothesis.  
Lastly, bearing in mind that HoP procedures works at a temperature of 62.5°C for 30 
minutes, in the present study we showed first that Activin A includes thermo-stability 
among its properties. This finding opens up to further investigations aimed at elucidating 
the protein stability under different conditions such as freezing and thawing procedures. 
In this respect, Lev et al. showed that storage at -80° can affect lipids and carbohydrates, 
whilst the total protein amount remains unchanged [38]. Finally, the present findings can 
be also of interest for further studies to investigate Activin A degradation during industrial 
processes aimed to prepare artificial milks, for which pasteurization and spray-drying 
procedures have been shown to affect milk composition and properties [28].  
Conclusion 
The present data on the absence of any side effects on Activin A milk concentration 
suggest the efficacy of HoP procedure in DM storage and preparation. The finding 
opens up to further investigations on neuro-biomarkers assessment in human milk and 
their pre-analytical stability according to storage procedures.  
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Abstract  
Purpose. Donor milk (DM) represents an important nutrition source for high-risk new-
borns. Holder pasteurization (HoP) is the most recommended procedure for DM treat-
ment, providing a good compromise between microbiological safety and biological 
quality. HoP was previously shown to affect DM cytokines, growth factors and hor-
mones levels, whilst no data concerning the possible effects of HoP on neurobiomarkers 
(NB) are available. Therefore, our study investigated whether the concentration in DM 
of a well-known NB involved in brain development/damage, namely S100B, changes 
due to HoP.  
Materials and Methods. We conducted a pretest-test study in 11 mothers, whose DM 
samples were sub-divided into two parts: the first was immediately frozen (-80°C); the 
second was pasteurized with Holder method before freezing. S100B DM levels were 
measured using a commercially available immunoluminometric assay.  
Results. S100B protein was detected in all milk samples. Results showed significant 
differences between groups (P<0.05) in S100B levels after HoP. 
Conclusions. Our data provide evidence that S100B is present in preterm milk as well as 
in term milk during maturation degree. Moreover, the results confirm the susceptibility 
of this neurotrophic factor to pasteurization stresses and the need to develop new 
storage techniques to preserve the biological quality of human milk. 
Key Words: Central Nervous System; Donor Human Milk; Human milk; Pasteurization 
Holder; S100B. 
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Introduction 
Despite technological improvement in milk-formulae milk research and industrial prepa-
ration procedures, there are still evidences on the unique composition of breast milk. 
This issue is of relevance especially in high risk newborn feeding in terms of multiorgan 
protection and infections prevention [1]. Therefore, the main target of neonatologists 
and biochemists points toward a wider use of breast milk in neonatal intensive care 
units (NICU) and to provide safer procedures for human milk storage and conservation 
[2]. This latter point is noteworthy since milk stored in Human Milk Banks (HMB) after 
pasteurization may present potential qualitative/quantitative changes in its composition 
[3]. Thus, the optimal pasteurization process should be able to provide as much as pos-
sible a safe and unaltered milk composition [3]. To date, Holder pasteurization (HoP) 
(62.5°C for 30 min) is the most studied and recommended method for the heat treat-
ment of donor human milk (DM) [2]. HoP provides a good compromise between micro-
biological safety and nutritional and biological quality of the human milk. Nonetheless, 
HoP inactivates or reduces some immunologic and anti-infective factors [4-6] whilst 
data on its effects on other constituents are unknown or still matter of investigation. 
This especially holds for neurobiomarkers (NB) such as neurotrophic factors and calcium 
binding proteins, including S100B protein, known to play a relevant role in brain devel-
opment [7,8]. 
S100B is an acidic calcium-binding protein, mainly concentrated in the central nerv-
ous system (CNS) and detectable in a variety of biological fluids including milk, where it 
is concentrated 200–300 fold higher than in other fluids [9,10]. Based on the protein’s 
main known activities (neurotrophic, brain damage marker), S100B regulates different 
cellular functions such as growth, intercellular communication, cellular transduction 
signal and cellular metabolism. Bearing in mind the unique properties of breast milk, 
S100B has been investigated both in human and milk-formulae milks [11]. Results 
showed that S100B levels: i) in maternal milk were higher than formulae-milks and cow-
milk [11]; ii) correlated with the degree of milk maturation [11]; iii) in formulae milks 
were affected by industrial preparation such as pasteurization and spray-drying proce-
dures [12]. In this regard, data on potential effects of HoP procedure on S100B levels in 
human milk are still lacking. 
Therefore, in the present study we investigated the effects of HoP on S100B milk 
concentrations from healthy mother donors. 
Materials and Methods 
We conducted a pre-test/test study, where the milk donors acted as their own controls. 
Milk samples (colostrum: n=11; transition: n=11; mature: n=11, respectively, defined 
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according to Playford et al.[13]) were collected from 11 healthy mothers from consecu-
tive singleton physiological pregnancies (Table 1).  
Exclusion criteria were multiple pregnancies, gestational diabetes and any maternal 
CNS illness; pregnancies carrying a fetus with any malformation and/or chromosomal 
abnormalities, systemic infection, intrauterine growth retardation, or cardiac or haemo-
lytic disease; mothers who were tobacco smokers, drugs and alcoholic addicted; use of 
drugs or pharmacologically active substances; mothers who received blood transfusions 
or blood products, or organ transplants; perinatal asphyxia and dystocia. 
The study protocol was approved by the local Ethic Committee of the Italian Associa-
tion of Human Milk Donor Banks. Mothers admitted into the study gave signed and 
informed consent.  
Collection and pasteurization of human milk 
Fresh milk samples were collected at the same time-point (9-10 am) into sterile, dispos-
able, high-density polyethylene sealed bottles (Flormed, Napoli, Italy). Milk was ob-
tained by emptying one breast completely by means of an electric breast pump (Medela 
Symphony, Baar, Switzerland). From the total amount of milk of each mother, a sample 
of 10 mL of milk was collected and then subdivided into two aliquots. The first was im-
mediately frozen at -80°C (NO-HoP), while the second aliquot was pasteurized and then 
frozen at -80°C (HoP). The HoP was performed with a Sterifeed pasteurizer (Medicare 
Colgate Ltd, Cullompton, UK) heating milk samples at 62,5° C for 30 minutes, then cool-
ing to 10°C in approximately 20 minutes by immersion into cold water. 
S100B measurements 
Samples were immediately stored at -80°C until measurement. The S100B was meas-
ured in all samples using a commercially available immunoluminometric assay (Liaison 
S100, DiaSorin, Saluggia, Italy) according to the manufacturer's instructions. Investiga-
tors who performed the laboratory tests were blind to storing modalities. The assay 
detection limit was 0.02 μg/L, the intra-assay CV was ≤5.0%, and the inter-assay CV was 
≤10%. The assay is specific for S100B, having been assessed by the manufacturer for a 
lack of cross reactivity with other proteins of the S100 family.  
Statistical Analysis 
S100B concentrations are expressed as median and interquartile ranges. Statistical 
analysis was performed by a comparison between groups using Mann–Whitney two-
sided U-test when the data did not follow a Gaussian distribution. A P<0.05 was consid-
ered significant. 
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Results 
Maternal and perinatal characteristics of the milk donors are reported in Table 1.  
All mothers showed normal clinical conditions. No overt neurological injury and/or 
infections were observed at the sampling time-points or at discharge from the hospital. 
Table 1. Demographic characteristics of milk donors.  
Parameters n=11 
Mean maternal age, years  35 
Parity 1 n. (total) 7 (11) 
Mode of delivery, n. (%) 
Caesarean 
Vaginal 
 
4 (35) 
7 (65) 
Gestational Age, wks 36 
Mean birth weight, g 2950 
Apgar score >7 n. (total) 
At 1 min 
At 5 min 
 
9 (11) 
10 (11) 
Gender male (female) 5 (6) 
 
S100B protein was detectable in all the measured milk samples. No significant differ-
ences (P>0.05, for all) have been found in S100B concentration when corrected for the 
degree of milk maturation. Moreover, S100B levels did not differ (P>0.05) between 
samples collected from mothers of preterm (median: 69.44 µg/L; 25° centile: 53.79 
µg/L; 75° centile: 71,66 µg/L) and term (median: 75.55 µg/L; 25° centile: 58.83 µg/L; 75° 
centile: 83.70 µg/L) infants after correction for gestational age. 
In Table 2 S100B levels before and after HoP procedure are reported. Significant dif-
ferences in S100B concentrations were observed in all milk samples before HoP and 
after HoP process (P>0.005). After correction for milk maturation degree, we observed 
a significant reduction after HoP in transitional milk and mature milk (P>0.05) but a no 
significant difference in colostrum after heat treatment (P<0.05).  
Table 2. S100B levels (µg/L) in milk in not pasteurized (NO-HoP) and pasteurized (HoP) groups. Data are ex-
pressed as median and interquartile ranges.  
Parameters All Samples (n=33) Colostrum (n=11) Transition  
(n=11) 
Mature  
(n=11) 
 Median 25% 75% Median 25% 75% Median 25% 75% Median 25% 75% 
NO-HoP 129.50 96.30 164.0 129.50 86.10 163.0 164.00 109.37 173.75 111.0 74.72 125.75 
HoP 70.00 41.60 109.0 72.80 26.40 110.0 83.40 70.00 110.50 41.60 15.92 68.9 
Chapter 4 
80 
Discussion 
Nowadays, mother milk still represents the first feeding choice for all neonates. This 
unique nutrient is of the utmost importance especially for sick children, who require 
mother milk to reduce the risk of complications related to prematurity such as necrotiz-
ing enterocolitis, sepsis and bronchopulmonary dysplasia [1]. In this respect, DM was 
shown to represent a valid alternative [3], thus supporting the need of HMB. Of note, 
HMB guidelines require that DM has to be pasteurized prior to use to inactivate viral 
and bacterial agents [2,13,14]. Heat treatment has been reported to affect, at least in 
part, the nutritional and immunological properties of human milk [4-6], although no 
information are available to date concerning the potential effects of HoP on human milk 
CNS constituents.  
The present study shows that HoP procedure affects the concentration in milk of a 
well-established CNS constituent, namely, the S100B protein. The difference in protein 
concentration regarded transitional and mature milks whilst no changes due to HoP 
procedure have been found in colostrum. Moreover, no differences among different 
degrees of milk maturation have been observed. The discrepancy with previous obser-
vations [9,11] may reside in different studied populations (term vs preterm-term).  
S100B levels detected in milk were considerably higher when compared to those of 
other biological fluids [9,10]. This latter finding is in agreement with previous observa-
tions [11] and is consistent with the notion that calcium binding proteins are highly 
concentrated in a biological fluid such as milk in which calcium is abundant [9,10,15]. 
The finding of different S100B concentrations before and after HoP procedure consti-
tutes the first observation on the effects of the pasteurization on the protein and de-
serves further consideration.  
In particular S100B has been shown to be: i) thermostable both at room tempera-
ture and after freezing from samples collected in different biological fluids [16,17]; ii) 
affected, in artificial milk, by techniques in use for industrial procedures, such as spray-
drying (180-185°C) [12], and iii) stable at pasteurization procedure applied in industrial 
procedures for treatment of milk formulae (70-72°C for 5-15 seconds) [12]. Altogether, 
bearing in mind that the HoP procedure consists of a heat treatment at 62.5° for 30 
minutes, the possibility that medium-low temperature but for longer time than indus-
trial procedures could affect S100B is consistent. Another explanation for the lower 
levels of S100B in DM may reside in the possibility that the epitopes of the protein have 
been modified during HoP, limiting the accuracy in the quantitative protein measure-
ment. In addition, the possibility that HoP could also affect S100B reducing or destroy-
ing its biological activity has to be taken into the due account. The finding is of rele-
vance since HoP has been previously shown to reduce the proteins, cytokines, growth 
factors and hormones content of milk [4-6]. Further studies on a wider study-population 
are thus needed in order to optimize CNS constituents measurement in milks as well as 
to improve DM components stability during treatment and storage processes. 
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The highest S100B levels pre-HoP and their decrease in milk concentrations follow-
ing HoP warrant further consideration. The former issue offers additional support con-
cerning the neurotrophic role of this NB [19]. In this regard, there is evidence both in 
humans and animal models on the trophic role of the protein in CNS fetal/neonatal 
development. In detail, S100B has been shown to: i) stimulate neurite outgrowth [20] 
trough a cascade of events in which nuclear translocation of NF-kB, up-regulation of Bcl-
2 in neurons and Receptor for Advanced Glycation End Products (RAGE) are involved 
[21,22], ii) exert a protective action on neurons, through a RAGE-mediated effect and 
the activation of the Cdc42/Rac signalling pathway, under physiological (development) 
and pathological conditions [23,24], iii) enhance hippocampal neurogenesis, and to 
prevent motor neuron degeneration after sciatic nerve section [25,26], iv) be involved 
in the mechanisms of modulating learning and memory [27], and v) be involved (in mice 
pups of immunized mothers that did not express S100B protein in their milk) in mor-
phological problems, a delay of the maturation of neurobehavioral systems and a deficit 
of neuromotor functions (i.e. visual abilities, somato-sensory and posture reactions, 
muscular strength, locomotion, and fear/orienting processes) [28]. Altogether, the evi-
dence that milk concentration of a brain constituent involved in CNS development and 
protection is affected by HoP strengthens the notion on the need of further studies 
aimed at limiting DM depletion thus empowering its unique role [3]. This issue can be of 
relevance especially for the feeding of high risk newborns. Further studies on a wider 
study-population are needed in order to corroborate S100B transfer from gut to sys-
temic circulation. In this regard, it has been recently observed that in the human gut, 
S100B protein is specifically and physiologically expressed and released in the gut by 
Enteric Glial Cells, morphological and functional equivalent of astrocytes and microglia 
in the CNS. The S100B protein can be considered as an easily diffusible pro-
inflammatory cytokine which gains access to the extracellular space especially during 
immune inflammatory reactions. [29] 
In conclusion, the present data suggest that HoP significantly modifies the concen-
tration of S100B. This finding opens up to further investigations on NBs assessment in 
human milk and their pre-analytical stability according to storage procedure. 
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Abstract 
Background. When mother’s own milk is not available, the best alternative is represent-
ed by donor milk (DM), i.e., human milk pasteurized with the Holder pasteurization 
(HoP) method in Human Milk Banks for safe storage. Advantages and disadvantages 
associated to this procedure have been widely discussed in Literature but currently 
represent the best compromise between microbiological safety and biological quality of 
DM. 
Objective. The aim of this study is to investigate the effects of HoP on Heme oxygenase-
1 (HO-1), an antioxidant protein involved in several cytoprotective actions that should 
play an important role in the development and protection of the gastro-enteric tract. 
Methods. We collected 42 milk samples and we performed a pretest-test study where 
the milk donors acted as their own controls in 14 mothers (who have delivered 7 at 
term and 7 preterm of Gestational Age). Milk samples were divided into two parts: the 
first was frozen (-80°C); the second was Holder-pasteurized before freezing (-80°C). HO-
1 was quantified using an ELISA test. 
Results. HO-1 was detected in all samples. There were no significant differences in HO-1 
concentrations between term and preterm milk samples (P>0.05). Likewise, no signifi-
cant differences in HO-1 content were found between raw and pasteurized milk sam-
ples (P>0.05). There were no significant differences when studied groups were correct-
ed for milk maturation degree (P>0.05). 
Conclusion. The data suggest that HO-1 does not significantly differ between preterm 
and term milk samples and that HoP does not affect HO-1 concentration in Human Milk. 
Key Words: Human milk; Donor Human Milk; Pasteurization Holder; Hemeoxygenase-1; 
Nutrition of preterm infants; NEC. 
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Background 
In literature, there are several evidences of the unique role of human milk for infant 
nutrition [1,2]. Feeding preterm and term infants with human milk is associated with 
significant long-term beneficial effects such as reduced risk of cardiovascular diseases, 
diabetes, obesity and cancer [1,3]. During the first months of life, short-term benefits 
are also present, such as supporting the development of the immune system and 
providing protection against infectious diseases [1]. When mother’s own milk is not 
available, the best alternative is represented by donor milk (DM), i.e., human milk pas-
teurized with the Holder pasteurization (HoP) method in Human Milk Banks (HMBs) for 
safe storage [4,5]. The available literature confirms the persistence of some of the ben-
efits of human milk also in donor milk, especially regarding the protection against Ne-
crotising Enterocolitis (NEC) for preterm newborns [6-9]. The short term benefit of HM 
and DM is supported probably not only by secretory immunoglobulin A but also by 
other immunologically active components such as antimicrobial factors, cytokines, 
chemokines and growth factors [10-13]. Additionally, the antioxidant properties at-
tributed to HM play a role of paramount interest, although the underlying mechanisms 
are still unclear [14,15]. The explanation may reside in the presence of antioxidant en-
zymes, an important group of which is constituted by heat shock proteins (HSPs), whose 
presence in biological fluids has been associated to the capacity of binding to specific 
cell surface receptors such as CD91 [16]. Among HSPs, heme oxygenase-1 (HO-1 or 
HSP32) is a stress-inducible rate-limiting enzyme in heme-catabolism which is associat-
ed to a strong cytoprotective effect [17] thanks to its multiple catalytic by-products. HO-
1 has recently been detected in different biological fluids (blood and cerebrospinal 
fluid), where its presence is reasonably related to its putative protective action [18,19]. 
Although the potentially important role of HO-1 in human milk, only one previous study 
has investigated the concentration of HO-1 in the HM of healthy mothers having deliv-
ered at term of Gestational Age. 
The present study will evaluate (a) the pattern of HO-1 in preterm and term human 
milk, over the transition from colostrum to mature milk; (b) the concentration of HO-1 
in donor milk, to evaluate the possible effect of HoP on this protein. 
Methods 
We performed a pre-test/test study, where milk donors acted as their own controls. 
Mothers admitted into the study gave signed and informed consent. The study protocol 
was approved by the local Ethic Committee of the Italian Association of Human Milk 
Donor Banks (AIBLUD). 
We enrolled 14 healthy mothers: 7 who have delivered at term (Gestational Age >37 
weeks) and 7 who have delivered preterm (Gestational Age <37 weeks) [20]. Samples 
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were collected from colostrum 48h after birth, from transition milk on Days 7 and 14, 
and from mature milk on Day 30 after birth (colostrum: n=14; transition: n=14; mature: 
n=14, respectively) [21]. Standard exclusion criteria for human milk donation set forth 
by AIBLUD guidelines were applied [4]. Moreover we excluded also: multiple pregnan-
cies, any CNS illness, gestational diabetes and hypertension, systemic infection, intrau-
terine growth retardation, cardiac or metabolic or hemolytic disease, malnutrition and 
maternal allergy and fetuses with any malformation and/or chromosomal abnormali-
ties. 
Collection and pasteurization of human milk 
Fresh milk samples were collected at the same time (9-10 a.m.) into sterile, disposable, 
high-density polyethylene sealed bottles (Flormed, Naples, Italy). Milk was collected 
with standard extraction methods by means of an electric breast pump (Medela Sym-
phony, Baar, Switzerland). According to current guidelines and in order to collect full 
pumping samples, the extraction session was stopped 2 minutes after the outflow of 
the last drops of milk [4,22]. From the total amount of milk of each mother, a sample of 
10 mL of milk was collected and then further divided into two parts. The first was im-
mediately frozen at -80°C (NO-HoP), while the second part was pasteurized and then 
frozen at -80°C (HoP). 
HoP was performed with a Sterifeed pasteurizer (Medicare Colgate Ltd, Cullompton, 
UK) heating milk samples at 62,5° C for 30 minutes, then cooling to 10°C in approxi-
mately 20 minutes by immersion into cold water. 
Heme oxygenase-1 measurements 
Samples were immediately stored at -80°C until analysis. Heme oxygenase-1 levels were 
determined using a specific ELISA test (SL0838HU-97 Human heme oxygenase 1 ELISA) 
according to the manufacturer's instructions (SungLong Biotech Co., Ltd.; China). Inves-
tigators who performed the laboratory tests were blind to storage modalities. The assay 
detection limit is 1.00 ng/ml, the coefficient of variability intra-assay is ≤ 5.0%, and the 
coefficient of variability inter-assay is ≤ 10%. The assay is specific for Heme oxygenase-1. 
Statistical Analysis 
Demographic characteristics of maternal and neonatal outcomes were reported as 
mean ± SD. HO-1 concentrations were expressed as median and interquartile ranges. 
Statistical analysis was performed by using two-tiled paired t-test and by Mann–
Whitney two-sided U-test when data did not follow a Gaussian distribution. Comparison 
between groups was performed by using ANOVA one-way test. A P<0.05 was consid-
ered significant. 
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Results 
Maternal and perinatal characteristics of milk donors are reported in Table 1. 
Table 1. Demographic characteristics of milk donors.  
Parameter n=14 
Mean (±SD) maternal age, years  35±5 
Parity 1 n. (total) 10 (14) 
Mode of delivery, n.  
Caesarean 
Vaginal 
 
5  
9  
Mean (±SD) gestational age, weeks 36±4  
Mean (±SD) birth weight, g 2950±1100 
Gender male (female) 6 (8) 
 
HO-1 was detectable in all human milk samples. Its concentration was higher in colos-
trum (median 74,8 ng/ml; 25° centile 59,1 ng/ml and 75° centile 83,7ng/ml) with respect 
to transition milk (median 64,2 ng/ml; 25° centile 52,9 ng/ml and 75° centile 77,7 ng/ml) 
and to mature milk (median 72,2 ng/ml; 25° centile 71,4 ng/ml and 75° centile 86,6 
ng/ml): nonetheless, the differences in HO-1 concentration were not significant, as 
represented in Figure 1 (P>0.05).  
 
 
Figure 1: Heme oxygenase-1 concentrations (ng/mL) in milk samples during maturation degree, before and 
after HoP. The lower and upper bars represent the 5° centile and 95° centile, respectively; interquartile range 
is indicated by the box and median value is represented by the horizontal line in the box . No significant 
differences have been found between studied groups (P>0,05). 
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After correction for gestational age, we can conclude that HO-1 does not significantly 
differ between preterm (median 69,4ng/ml; 25° centile 53,7ng/ml and 75° centile 
71,6ng/ml) and term milk samples (median 75,5ng/ml; 25° centile 58,8ng/ml and 75° 
centile 83,7ng/ml), P>0.05 (Figure 2). 
 
 
Figure 2: Heme oxygenase-1 concentrations (ng/mL) in preterm and term samples, before and after HoP. The 
lower and upper bars represent the 5° centile and 95° centile, respectively; interquartile range is indicated by 
the box and median value is represented by the horizontal line in the box . No significant differences have 
been found between studied groups (P>0,05). 
 
HO-1 was detectable also in all pasteurized milk samples, as shown in Figure 1. No sig-
nificant differences in HO-1 levels were observed in all milk samples before HoP (medi-
an 71,4ng/ml; 25° centile 57,0ng/ml and 75° centile 83,5ng/ml) and after HoP (median 
53,7ng/ml; 25° centile 50,7ng/ml and 75° centile 73,8ng/ml) (P>0.05). No significant 
differences (P>0.05) have been found between groups when HO-1 concentrations were 
compared sub-grouping for gestational age (term vs preterm) (Figure 2). Furthermore, 
HO-1 levels did not differ (P>0.05, for both) in both groups when compared for the 
degree of milk maturation (Figure 1). 
Discussion 
Human milk contains several biological factors that are involved in a newborn’s growth 
and immune system regulation, and which are fundamental to ensure protection 
against infection and to prevent NEC in preterm newborns [1,23]. Among these factors, 
HO-1 is an antioxidant protein and an enzyme of the Heat Shock Protein group which 
has been associated to important cytoprotective actions [23-27]. 
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Our study is the first to show that HO-1 is present in preterm human milk and in do-
nor milk. No statistically significant differences were found between preterm and term 
milk samples; likewise, our results showed a not significant decrease in HO-1 levels as 
the milk matures, in both term and preterm milk. These findings are in agreement with 
the notion that the concentrations of colostrum and milk constituents change with 
suckling time. Only one study was conducted previously in order to evaluate the pres-
ence of HO-1 in term human milk [28]. Our data are in agreement with the results of Li 
Volti et al., although we did not find significant differences between colostrum and 
mature milk [28]. The presence of a typical intracellular protein such as HO-1 in milk is 
consistent with previous observations demonstrating the presence of other intracellular 
proteins (e.g., α-lactalbumin, calmodulin and osteocalcin) in extracellular space and/or 
biological fluids. The presence of such proteins in milk is related to an active secretory 
mechanism and/or to the anatomical and physiological characteristics of the mammary 
gland (i.e., apocrine mechanism of secretion). 
Moreover our study is the first that evaluates the effect of HoP on HO-1 levels in 
human milk. The data show that this heat treatment does not affect significantly HO-1 
concentrations also after correction for gestational age and maturation degree of the 
human milk. Currently, Holder pasteurization (62.5°C for 30 minutes) is the most stud-
ied and recommended method for the heat treatment of donor human milk in Human 
Milk Banks, since it represents a good compromise between microbiological safety and 
nutritional and biological quality of the human milk [4,5]. In fact, this method is able to 
inactivate milk pathogens but partially degrades immunologic and anti-infective factors 
such as IgA, IgG, lysozyme, lactoferrin, lymphocytes, growth factors and lipase as well 
[29,30]. Nonetheless, with Holder pasteurization other key nutritional factors (i.e., oli-
gosaccharides, lactose, LCPUFA, fatty acids and vitamins) remain unaffected [29,31]. 
The loss of biological factors through pasteurization may have significant implications 
and this is particularly important in preterm infants with an immature immune system, 
who are at increased risk of developing necrotizing enterocolitis (NEC). 
In particular milk HO-1, similarly to other milk antioxidant enzymes, may exert pro-
tection via its antioxidant activity, which is related to the conversion of free heme into 
three end products: (i) biliverdin, which is rapidly reduced into bilirubin (which itself 
possesses antioxidant activity) [32]; (ii) carbon monoxide, a potential gaseous neuro-
transmitter and vasodilator with anti-inflammatory and antiapoptotic activities [17]; and 
(iii) iron (Fe2+), which is sequestered by iron-binding proteins [33,34]. Moreover HO-1 
has probably an immunoregulatory role that is not only dependent on its enzymatic 
activity but is related to its ability to bind specific receptors, thus regulating the immune 
response. In fact extracellular stress proteins, including HSP, are emerging as important 
mediators of intercellular signaling and transport [35,36]. Release of such proteins from 
cells is triggered by behavioral stress, as well as by exposure to immunological “danger 
signals” [34]. After release into extracellular fluid, HSP may then bind to the surfaces of 
adjacent cells and initiate signal transduction cascades, as well as transport of cargo 
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molecules such as antigenic peptides and chaperokines with an immunomodulatory 
effect [16]. In particular, Li Volti et al., using a molecular modeling approach, found that 
an important immunoregulatory receptor (i.e., CD91) is the possible ligands of HO-1. 
Nevertheless, integrating experimental data with in silico data also highlighted the puta-
tive role for HO-1 as an immunomodulatory molecule [28]. 
Bearing in mind the different functions of HO-1 in several tissue, the data reported 
in literature by four meta-analysis showing a reduction in NEC incidence in preterm 
babies fed with donor milk compared to those fed with preterm formula [6-9], and the 
unclear pathophysiology of NEC (immature gastrointestinal epithelium, impaired immu-
nological defences, enteral feeding and bacterial colonization), it is possible to argue 
that human milk HO-1 may play a role in development and regulation of immune sys-
tem of the gastroenteric tract. 
Conclusion 
Our study showed that HO-1 is present not only in term human milk but also in preterm 
human milk in similar concentrations. Additionally, our data suggest that the biological 
value of human milk associated with the HO-1 content is maintained after Holder pas-
teurization. Further data concerning the metabolic fate of HO-1 in the gastro-enteric 
tract is needed to corroborate the hypothesis that HO-1 participates in the nutritional 
and immunoregulatory effects of milk. 
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Abstract 
Introduction. Under some circumstances Human Milk (HM) extraction and refrigerated 
storage may be necessary. Depending on the length and on the type of cold storage, 
milk may lose some important properties but current advices on safe HM storage are 
discordant. Moreover until now no data in literature was present on the effect of pro-
longed cold storage on biological active components of the HM such as Adrenomedullin 
(AM). This important peptide is involved in response to hypoxia and inflammation, asso-
ciated with neovascularization, in several tissues. The aim is evaluate: (a) the presence 
of AM in preterm and term human milk; (b) the concentration of AM in refrigerated 
milk at 4°C at 24h intervals, up to 96 hours of storage. 
Materials and Methods. The experiment was repeated 4 times. Immediately after collec-
tion, each HM sample deriving from each mother was divided into two parts: “Pool” line 
and “Single Mother” line. One part (Pool line) was pooled and then divided into 5 ali-
quots. The other part (Single Mother line) was divided into 5 aliquots. From each line, 
one aliquot, was analyzed within 3 hours, while the others were stored in the refrigera-
tor for 24, 48, 72 and 96 hours, respectively and then analyzed. AM levels were deter-
mined using a specific ELISA test. 
Results. AM was detectable in all samples. Its concentration was significant higher in 
preterm milk with respect to term milk (P<0.05). Significant differences were observed 
during the cold storage: the AM levels decreased steadily during the storage and the 
remaining concentration at 96 hours is approximately 2%. 
Discussion. This study provides evidences regarding the presence of AM in HM, regard-
less of the gestational age. In particular, the refrigeration of fresh human milk in con-
trolled conditions significantly affected its bioactivity and nutritional quality related with 
AM, already at 24 hours. 
Key Words: Adrenomedullin; refrigeration; cold storage; human milk, nutrition. 
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Background 
Breastfeeding is the gold standard nutrition for infants [1]. However, breastfeeding is 
not always possible and, under some circumstances (mainly in Neonatal Intensive Care 
Units), HM extraction and refrigerated storage may be necessary. Moreover, the stor-
age of refrigerated milk may also be performed at home for milk to be donated to milk 
banks, or for later use by the mother’s own infant. Depending on the length and on the 
type of cold storage, HM may lose some important nutritional and functional proper-
ties. Current advices on safe HM storage are discordant [2-4] due to the variability of 
the findings reported in the literature [5]. Recent studies highlighted that the total pro-
tein count and the protein profile were not affected by refrigerated storage at 4°C for 
96 hours and Giribaldi et al. observed that the refrigeration process did not affect the 
abundance of important nutritional markers such as the available Lysine, sIgA, lactofer-
rin and Lysozyme content [6,7]. On the other hand, until now, no data in literature was 
present concerning the effect of prolonged cold storage on several biological active 
components of the HM.  
Adrenomedullin (AM) is a C-amidated peptide, involved in response to hypoxia and 
inflammation, which are associated also with neovascularization. Recent studies indi-
cate that AM is synthesized also in the mammary gland and secreted in breast milk [8], 
although the data are discordant on its concentration in milk of mothers having deliv-
ered at term of the gestational age. On the other hand the presence of AM in HM and 
the variation in its concentration between the different milk maturation degrees and 
between healthy and pathological mothers suggest that AM may have an important role 
in the regulation of growth and maturation of the neonatal gastrointestinal tract [9-11]. 
In order to elucidate some of the uncertainties regarding AM in human milk, we 
evaluated: (a) the presence of AM in term and also in preterm human milk; (b) the ef-
fect on AM concentration in refrigerated milk at 4°C at 24h intervals, up to 96 hours of 
storage. 
Methods 
Sample collection 
HM samples were collected at the Neonatal Intensive Care Unit (NICU) of the University 
of Turin, from healthy mothers having delivered preterm and at term of gestational age. 
Standard exclusion criteria for human milk donation set forth by AIBLUD guidelines 
were also applied [3]. Mothers admitted into the study gave signed and informed con-
sent. The study protocol was approved by the local Ethic Committee of the Italian Asso-
ciation of Human Milk Donor Banks (AIBLUD). The experiment was repeated 4 times to 
ensure reproducibility of the results, we enrolled 3 mothers for each time (total donat-
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ing healthy mothers: 12). Fresh milk samples were collected at the same time (9-10 
a.m.) into sterile, disposable, high-density polyethylene sealed bottles (Flormed, Naples, 
Italy). Milk was collected with standard extraction methods by means of an electric 
breast pump (Medela Symphony, Baar, Switzerland). Immediately after collection, each 
HM sample deriving from each mother was divided into two parts: “Pool” line and “Sin-
gle Mother” line. The “Pool” line part was pooled in a sterile bottle with the other 
“Pool” line parts deriving from the other 2 mothers (total volume: 50 ml) and then di-
vided into 5 aliquots. The “Single Mother” line part was immediately divided into 5 
aliquots. From each line, one aliquot, (0h) was immediately frozen at -80°C until the 
analysis. The others aliquots (24h, 48h, 72h, 96h) were stored in the refrigerator at 4°C 
in the NICU respectively for 24, 48, 72 and 96 hours, and then immediately frozen at -
80°C until the analysis . The replicate pools were kept separated and analyzed inde-
pendently. The temperature of the refrigerator was constantly monitored by two mini 
data loggers equipped with internal probes (Testo 174T, Lenzkirch, Germany) placed on 
the bottom and top shelves of the NICU fridge, and programmed to record the temper-
ature every 5 minutes. 
Adrenomedullin analysis 
Adrenomedullin levels were determined using a specific ELISA test (SL007HU- Human 
adrenomedullin -ADM- ELISA KIT) according to the manufacturer's instructions (Sun-
gLong Biotech Co.Ltd.;China). Investigators who performed the laboratory tests were 
blind to storage modalities. The assay detection limit is 0.05 ng/L, the assay range is 2 
ng/L-40 ng/L. The assay is specific for Human AM.  
Statistical analysis 
Demographic characteristics of maternal and neonatal outcomes were reported as 
mean ± SD. Adrenomedullin concentrations were expressed as mean ± SD. Statistical 
analysis was performed by using two-tiled paired t-test and by Mann–Whitney two-
sided U-test when data did not follow a Gaussian distribution. Comparison between 
groups was performed by using ANOVA one-way test for multiple comparisons. A 
P<0.05 was considered significant. 
Results 
Demographic Characteristics 
The 12 donor mothers were healthy women having delivered; 6 at term (Mean gesta-
tional age at birth: 39+/- 1weeks; mean birth weight: 3010+/- 220g) and 6 preterm 
(mean gestational age at birth: 30 +/- 1weeks; mean birth weight: 1650 +/- 140g). 8 
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mothers delivered by Vaginal and 4 by Cesarean Section. 5 newborns were males and 7 
females. The mean date of delivery was one month before the donations. 
Adrenomedullin levels 
Adrenomedullin was detectable in all human milk samples. Its concentration was higher 
in preterm milk (mean: 200,0 ng/L; SD +/- 189,9 ng/L) with respect to term milk (mean 
18,1 ng/L; SD +/-10.9 ng/L) and the differences in concentration were significant 
(P<0.05). AM was detectable also in all refrigerated milk samples, Table 1.  
Table 1 Adrenomedullin concentrations (ng/L) in human milk during the cold storage. Data are expressed as 
mean and SD. 
AM 0h 24h 48h 72h 96h 
TS 272.8 ±195.3 120.1 ± 140.3 20.55 ± 6.3 13.9 ± 6.8 7.3 ±4.8 
PL 341.4 ±132.5 234.3 ± 178.7 23.3 ± 2.1 12.4 ± 8.3 7.3 ±6.2 
SML 242.3 ±217.4 69.4 ± 90.2 19.3 ± 7.2 14.5 ± 6.6 7.3 ±4.5 
Abbreviations: Total sample, TS; pool line, PL; single mother line, SML.  
 
 
Figure 1 Adrenomedullin concentrations (ng/L) in total human milk samples during the cold storage at 4°C for 
96 hours. The lower and upper bars represent the 5th and 95th centiles, respectively; interquartile range is 
indicated by the box and median value is represented by the horizontal line in the box.  
* Significant differences between T0h and the other time points (P<0,05). 
 
As shown in Figure 1, significant differences in AM levels were observed during the cold 
storage. The data show a significant reduction of 56% in concentrations in all samples at 
24 hours. The AM levels decreased steadily during the storage and the remaining con-
centration at 96 hours is approximately 2%. This trend of reduction is similar in the 
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“Pool” line and in the “Single mother” line. Indeed, a significant difference (P<0.05) was 
found also when AM concentrations in milk samples were corrected for gestational age. 
Discussion 
The biologically active components found in human milk participate in multiple physio-
logical processes including modulation of gastrointestinal functions, microbial growth 
control and immunoregulation [12]. Cold storage of human milk is a common practice 
both in hospitals and at home, but the effect on these components is already unclear. 
The maximum refrigeration time for human milk ranges between 24 hours and 8 days, 
according to current advices. Such variability reflects the heterogeneity of the scientific 
sources, which can be attributed to differences in the study design and in the methodo-
logical approaches [5]. Recent studies concluded that human milk can be stored for 96h 
at 4°C without affecting the overall milk integrity but several important biological com-
pounds were not considered at all [6,7].  
Our study shows that prolonged refrigeration of HM at 4°C affects its original con-
tent of adrenomedullin. This protein is not thermostable at 4°C: AM is significant re-
duced (56%) at 24h and is nearly undetectable at 96h. We performed our analysis not 
only in HM pool but also in HM samples deriving from the single mothers in order to 
compare the results on two different modality of storage of HM (Human milk banks and 
home, respectively). Our data shown that the model of AM decrease is similar in both 
lines. Moreover we related the decrease content of the AM only at prolonged refriger-
ated storage because the protein stability, under different conditions such as freezing 
and thawing procedures, are certain. In this respect, Lev et al. [13] showed that the 
total protein amount remains unchanged during the storage at -80°c; data confirmed by 
Ahrabi et al. regarding the freezer storage, at -20°C, of human milk for up to 9 months 
for refrigerated milk [14]. The thawing procedures were investigated recently by Handa 
et al. [15] and no changes in protein were observed between processing methods of 
thawing and warming of human milk. 
We detected AM in all HM samples collected and these data are in agreement with 
the literature. Before the discovery of the presence of AM in mouse milk [8], 3 previous 
studies have evaluated the presence of the AM in human milk. Pio et al. and Ohta et al. 
focused their studies in human milk of healthy mothers having delivered at term and 
obtained discordant results on AM concentrations [9-11]. Ohta et. al detected AM only 
in 21% of samples (assay system IRMA) vs results of Pio et al., who found AM in all milk 
samples (radioimmunoasssay RIA). Cekmen et al. analyzed HM of healthy and 
preeclamptic women and found AM in all samples (HPLC) [9-11].  
Our data show for the first time the presence of this important peptide also in HM 
of mother having delivered preterm infants and demonstrate that AM levels in preterm 
milk are significantly higher in respect to the term milk. Our results are in agreement 
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with the previous literature demonstrating that AM levels in HM are higher than those 
reported in plasma: several human hormones and growth factors present in milk exceed 
their plasma concentration [16]. Anyway, the finding of significant changes in AM levels 
herein reported warrants further considerations. AM is a regulatory peptide and its 
expression was demonstrated in several tissues and biologic fluids such as plasma, 
cerebro-spinal fluid, sweat, amniotic fluid and urine [17-19]. AM has been implicated in 
the modulation of several physiological functions including cardiovascular tone [20], 
central brain activity [21-24], bronchodilation [25], renal function [26], hormone secre-
tion [27], cell growth-differentiation [28] and immune response [29,30]. Moreover AM 
has been investigated for its involvement in ischemia-reperfusion injury whilst in 
healthy infants has been shown to participate in the cascade of events promoting fe-
tal/neonatal cardiovascular adaptation [22-24]. AM has been also assessed for evalua-
tion of beneficial/side-effects of in-utero vasodilation therapeutic strategies in pregnan-
cies complicated by fetal chronic hypoxia [22-24]. In this regard, an observation on AM 
and the occurrence of adverse neurological outcome has been reported in infants with 
congenital heart disease [22-24]. Bearing in mind these important functions, it is possi-
ble to speculate that the presence of the active peptide AM in HM, and their variability 
in concentrations between milk degree (from colostrum to mature milk), gestational 
pathologies and gestational age of delivery, could have some direct impact in the devel-
opment of the neonate due to the several physiological activities that have been associ-
ated to it. In relation with the gastrointestinal tract, immunoreactive AM has been de-
tected in human stomach, duodenum, jejunum, ileum and colon [31], and specific bind-
ing sites have been detected in rat stomach [32]. This distribution suggests a role for 
AM in the regulation of secretory-motor functions in the gastrointestinal tract, as well 
as in its development during the embryogenesis and the period immediately following 
birth. Since the developing intestine in the neonate is considered to be one of the main 
target organs for the growth factors present in human milk, Pio et al. [9] demonstrated 
that milk has a growth-promoting activity on human small intestinal epithelial cell line 
(Int-407). These authors suggest that since MoAb-G6 partially blocks the milk-induced 
growth, AM may be one of the growth factors present in milk. AM has also been de-
scribed as an agent with antimicrobial activity against gastrointestinal microorganisms 
[29,30]. This activity could be important for the protection of the neonate against gas-
troenteritis produced by intestinal pathogens. In the and, since some peptides are ab-
sorbed from the neonatal gastrointestinal tract and appear intact in plasma, [33] AM 
could also exert an activity in the modulation of tissue growth as well as in the regula-
tion of the immune system. 
Finally, the present findings can also be of interest for future studies aimed at inves-
tigating the variability of AM concentrations in colostrum/transitional/mature milk un-
der the same storage conditions and in the different gestational age of delivery. Moreo-
ver, it would be interesting to correlate the AM milk levels with the following parame-
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ters: AM plasma levels in mothers, frequency of breastfeeding, type of delivery, number 
of births and also with gestational pathologies. 
Conclusion 
In conclusion, this study provides new and incremental evidences regarding the pres-
ence of adrenomedulin in human milk, regardless of the gestational age at delivery. In 
particular, refrigeration of fresh human milk in controlled conditions for 96 hours signif-
icantly affected its bioactivity and nutritional quality related with adrenomedullin. 
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Summary and Discussion 
Recently, several studies have emphasized that fresh own mother’s breast milk is the 
first choice in preterm infant feeding and that strong efforts should be made to pro-
mote lactation [1]. For this reason, it has been the goal of international neonatal net-
works to increase breastfeeding rates at discharge from the NICU above the threshold 
of >20%. Nonetheless, when mother’s own milk is not available, DM is highly recom-
mended [1]. DM should be provided from an established HMB, which has to follow 
specific safety guidelines [2]. The presence of a HMB does not decrease breast-feeding 
rates at discharge, but decreases the use of formula during the first weeks of life [3].  
Among the reported evidence of the benefits in preterm newborns deriving from 
the use of DM, protection against NEC is particularly important and should be highlight-
ed [4]. The potential advantages of unfortified DM on improved feeding tolerance and a 
reduced cardiovascular risk during adolescence are still a matter of debate [3].  
Storage and processing of HM reduce some of its biological components, which may 
lose, in part, some of their health benefits. From a nutritional point of view, DM (like 
HM) is constantly subject of research since new molecules involved in developmental 
processes have been identified, such as the “trophic factors” [5].  
Future research should focus on improvements of milk processing in HMB (particu-
larly heat treatment) and on further evaluation of the potential clinical benefits of pro-
cessed and fortified DM. 
*** 
In Chapter 1 we have provided an overview of the main findings related to the effects of 
HoP on the biological and nutritive components of DM and have shown a high variability 
among literature data. Apparently it is very difficult to quantify the actual effects of HoP 
on the biological and nutritional properties of the milk. Substantial discrepancies exist 
not only between the protocols applied in different studies but also between the stand-
ard operating procedures adopted by HMBs and the experimental methods reported in 
research protocols. When pasteurization is performed for research purposes, it is usual-
ly carried out with laboratory-scale equipment, which is not equivalent to the pasteuri-
zation environment used in HMBs [6,7]. Moreover, samples submitted to thermal 
treatment in laboratories often consist of a few milliliters of milk (typically less than 10 
mL) [7,8], whereas HMBs routinely use industrial pasteurizers, specifically designed and 
validated for the pasteurization of larger quantities of human milk (up to 200 mL of milk 
for each container). Another limitation is the fact that several studies do not provide 
precise information concerning the equipment used and the pasteurization parameters 
applied in the study (e.g., time, temperature, and duration of the different phases of the 
processing) [9,10]. Furthermore, conditions applied in research protocols for milk ex-
pression, handling, processing and storage before analysis are extremely variable, 
whereas storage conditions in HMBs are standardized and well defined by written pro-
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tocols [6-13]. Based on these considerations, it is not surprising that significant differ-
ences are present when comparing results obtained in clinical practice and research 
conditions. Thus, it remains a matter of debate whether the studies available in litera-
ture adequately describe the impact of HoP on milk properties and if the nutritional 
qualities of milk are preserved after pasteurization.  
Altogether, the available data show that HoP affects several HM components, even 
though it is rather difficult to quantify the degradation level. Additionally, it appears 
that some biochemical patterns have been investigated more extensively than others, 
whereas some milk components were not considered at all. Proteins are more signifi-
cantly affected by HoP but the results concerning specific biologically active molecules 
(such as cytokines and growth factors) remain uncertain, due to the vast number of 
different compounds analyzed in each study and to the paucity of comparable results.  
Our studies were designed to investigate HoP adapting the protocols to match the 
actual procedures of storage, handling and processing of donor milk practiced by HMBs, 
to provide results relevant for the actual clinical management of DM. 
In Chapter 2 we evaluated the effect of HoP on the protein profile using a semi-
quantitative GeLC-MS analysis technique. GeLC-MS was chosen as it is particularly well-
suited to evaluate the complex array of biologically active proteins composing the HM 
protein profile. Samples obtained from different donors reacted differently to heat 
treatment although processed and stored at the same conditions. Briefly, about 30% of 
the samples analyzed showed differences in the protein profile after HoP, whereas the 
remaining 70% did not. The main detectable protein profile changes were observed in 
colostrum, thus providing further support to the use of DM since no evident changes 
were shown in mature milk. These findings deserve further investigation. Specifically, 
the main open question concerns the interactions between proteins and sugars or lipids 
due to thermic treatments, with the possible generation of inactive (or even toxic) de-
rivatives.  
In Chapter 3 we investigated the effects of HoP on the DM concentration of a well-
established biomarker of CNS development/damage, namely Activin A. Results showed 
that HoP does not affect Activin A concentrations in DM at different milk maturation 
degrees. Furthermore, the present study showed first the presence of Activin A in milk 
collected from preterm deliveries. The loss of biological factors through pasteurization 
may have significant implications; this is particularly important in preterm infants with 
an immature immune system, who are at increased risk of developing NEC. The evi-
dence that HoP guarantees an unaltered Activin A intake to the newborn further con-
firms the benefits of feeding preterm newborns with DM as compared to artificial milk 
[14]. This is of relevance considering that artificial milk industrial preparation proce-
dures have been shown to affect to a significant extent both the milk composition and 
properties [15]. Moreover, an unaffected Activin A concentration in DM is important 
since on the basis of several studies it is reasonable to assume that Activin A is involved 
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in embryogenesis and exerts a unique trophic effect in biological fluids [16]. In fact, 
Activin A, its receptors and binding proteins are widely distributed throughout the brain 
[16]. Studies in experimental models and in case of acute brain injury in the human 
strongly correlate enhanced Activin A expression as a common response to acute neu-
ronal damage of various origins. Even interesting is the finding that Activin A is able to 
support the survival of neurogenic cell lines and neurons and to offer protection against 
neurotoxic damage [17]. Moreover up-regulation of this neurotrophic factor by antide-
pressant treatment and atrophy of limbic brain regions in response to stress or in de-
pressed patients has resulted in a neurotrophic hypothesis of depression [18] 
HM is believed to contain biological factors involved in the regulation of newborn 
growth, including brain development. Moreover the presence of S100B, a calcium-
binding protein in a biological fluid such as milk, in which calcium is abundant, is not 
surprising in the light of the consideration that other calcium-binding proteins (e.g. 
alpha-lactalbumin, calmodulin, osteocalcin) have already been detected in milk [19-21].  
Therefore, in Chapter 4 we investigated whether HoP procedure could somehow affect 
the neurotrophic S100B protein. Results showed an “unexpected” susceptibility of the 
protein to HoP, especially in transitional and mature milks, whereas no differences were 
detectable in colostrum. These finding deserve further consideration. The available data 
confirm that i) S100B collected from different biological fluids is stable both at low and 
room temperature for long time [19,22], ii) industrial pasteurization procedures for 
treatment of milk formulae (70-72°C for 5-15 seconds) do not affect S100B [15], and iii) 
S100B is affected by industrial spray-drying techniques (180-185°C) [15]. Overall it is 
possible to conclude that temperature per se does not affect S100B characteristics. 
Nonetheless, bearing in mind that the HoP procedure consists of a heat treatment at 
62.5° for 30 minutes, the possibility that medium-low temperature for longer time 
could affect S100B is quite well possible. Another explanation for the lower levels of 
S100B in DM may reside in the possibility that the epitopes of the protein are modified 
during HoP, limiting the accuracy in the quantitative protein measurement. In addition, 
the possibility that HoP could also affect S100B by reducing or destroying its biological 
activity has to be taken into account.  
In Chapter 5 we studied the effects of HoP on heat shock proteins (HSPs) such as HO-1. 
Among the several functions of HM, antioxidant properties have also been attributed 
[23]: the explanation may reside in the presence of antioxidant enzymes and HSPs that 
have been related to the capacity of binding to specific cell surface receptors such as 
CD91 [24]. CD91 is an important immunoregulatory receptor that has been previously 
identified as a receptor for the serum protein α2-macroglobulin (a ‘natural’ protease 
inhibitor) and then as a common receptor for all identified HSPs [25,26]. An increasing 
body of evidence suggests that CD91 represents an important route for stimulating a 
CD8+ T-cell response by major-histocompatibility-complex-class-I-restricted presenta-
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tion. This may also be a fairly general mechanism by which the innate immune system 
may stimulate the adaptive arm in viral infections and tumors [27].  
Among HSPs, HO-1 is the rate-limiting enzyme in heme catabolism that is associated 
with strong protective effects [28]. The presence of HO-1 has been recently detected in 
biological fluids (blood, cerebrospinal fluid, and milk), where it is likely involved in sev-
eral cytoprotective actions. In milk, HO-1 should be also involved in the development 
and protection of the gastro-enteric tract [29,30]. In particular milk HO-1, similarly to 
other milk antioxidant enzymes, may exert protection via its antioxidant activity and 
HO-1 has probably an immunoregulatory role related to its ability to bind specific recep-
tors, such as antigenic peptides and chaperokines.  
Our study showed that HO-1 is present in preterm HM and in DM. No statistically 
significant differences were found between preterm and term milk samples; likewise, 
our results showed a non-significant decrease in HO-1 levels as the milk matures, in 
both term and preterm milk. Moreover, our data showed that this heat treatment does 
not affect HO-1 concentrations also after correction for gestational age and maturation 
degree of the human milk. 
Bearing in mind the different functions of HO-1 in several tissues and specifically in 
development and regulation of immune system of the gastro-enteric tract, it is evident 
that HO-1 is unaffected by heat treatment. Its thermostability confirms the biological 
value of HM associated with the HO-1 content in preterm babies fed with DM. 
Finally, in Chapter 6 we evaluated the effect of cold storage on AM concentration. Our 
results showed for the first time that AM levels are: i) detectable in HM, ii) higher in HM 
of preterm infants, and iii) affected by freezing procedure.  
The first issue is of relevance due to AM localization of AM especially in the cardio-
vascular and central nervous sytem. Taking into account that AM is synthesized in the 
mammary gland, it is reasonable to assume that its site of releasing and concentration 
could only be breast milk [31]. However, further investigations performing western-blot 
analysis and RT-PCR will elucidate whether AM measured in HM corresponds to that 
currently measured in different biological fluids [32-34].  
The second issue offers additional support to the gastrointestinal tract localization 
of the peptide [35], to its differences in concentration according to different milk matu-
ration degrees and between healthy mothers and those with diseases [36-38]. Alto-
gether it has been suggested that AM may have an important role in the regulation of 
secretory-motor functions growth and maturation of the neonatal gastrointestinal tract, 
as well as in its development during the embryogenesis.  
Lastly, the third point showed that AM levels are affected by storage procedures de-
creasing AM levels, at 96-h from storage, up to 98% of the total peptide amount [39-
41]. Among different AM functions it has also been reported to act as an antimicrobial 
agent in the gastrointestinal tract [42,43]. Thus, the finding of higher AM levels detect-
ed in HM of preterm infants suggests a trophic role of the peptide at this period. These 
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data are in agreement with other studies showing that different neuro-biomarker con-
centrations (i.e. activin A and S100B) are gestational age dependent [44,45]. The fact is 
of relevance in terms of different vascular, neuronal arborization and immune system 
maturation and higher occurrence of NEC. Thus future perspectives should regard not 
only the optimization/creation of storage procedures but also technological improve-
ment in biomarkers assessment in a complex biological fluid such as milk.  
Conclusions and Future Perspectives  
The present thesis contributes to a better understanding of the potential effect of stor-
age on HM and primarily on the effects of HoP on DM. However, many questions re-
main to be answered. In particular, future studies must be aimed at improving the bio-
logical quality and safety of DM and should be: i) designed to investigate the pre-
analytical stability of these components according to the storage procedures; ii) intend-
ed to evaluate innovative test technologies, such as metabolomics; iii) focused on new 
pasteurization techniques (high-temperature short-term pasteurization, thermos-
ultrasonic treatment, high-pressure processing, and Ohmic heat treatment); iv) aimed 
to evaluate analytical techniques able to assess the protein changes due to thermic 
treatments, as well as their interaction with sugars and lipids; v) designed to evaluate 
the effects of HoP on other biomarkers involved in growth and developing of newborns. 
Moreover our findings open up to further investigations aimed at elucidating the 
protein stability during industrial processes for the preparation of artificial milk such as 
pasteurization and spray-drying, which have already been shown to affect milk compo-
sition and properties. 
Further data concerning the metabolic fate of the most important milk biomarkers 
in the gastro-enteric tract is needed to corroborate the hypothesis that these partici-
pate in the nutritional effects of milk and in its immuno-regulatory and trophic role for 
intestine and brain development. In this setting, neuro and calcium binding proteins, 
vasoactive agents, oxidative stress markers are involved in the known (patho-) physio-
logical steps in multiorgan growth. The possibility to evaluate the concentrations of 
these elements in DM or in artificial milk will be the first step to elaborate specific ther-
apeutic strategies in selected newborns. This means that biomarkers are of potential 
relevance to provide useful supplementation in future therapeutic protocols, being able 
to empower neuro/enteral-protection at different timing and length of administrations. 
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The aim of this thesis was to investigate the effects of storage on specific HM constitu-
ents. In detail, the issues addressed are:  
i) the state of art of HoP effects on HM composition; 
ii) the changes in HM qualitative protein profile following HoP procedure;  
iii) the potential side-effects due to HP procedure on biomarkers such as Activin A, 
S100B, HO-1; 
iv) the potential side-effects due to prolonged refrigerated storage on AM. 
Relevance: Fresh own mother’s breast milk is considered the first choice in preterm 
infant feeding, and is able to provide health benefits that are of vital importance for 
preterm infants in NICUs. HM feeding in preterm infants decreases infection, NEC and 
mortality rates, while improves neurocognitive and cardiovascular outcomes. HM can 
be considered a species-specific biological "dynamic" system, containing bioactive and 
immunomodulatory factors which ensure adequate host defense against infections, 
actively modulate the immune response, modify the intestinal bacterial flora and, regu-
late optimal newborn growth including CNS. Selected biomarkers have a special role in 
human milk, such as: i) Neurotrophic factors — activin A; ii) calcium binding proteins — 
S100B; iii) oxidative stress biomarkers —HO-1, iv) vasoactive agents – AM. For this rea-
son, international neonatal networks are committed to increase breastfeeding rates at 
discharge from the NICU whenever possible.  
When mother’s own milk is not available, the use of DM is highly recommended 
since it retains most of these benefits. DM must be sourced from established HMB 
under specific safety guidelines for storage and processing, which foresee a HoP requir-
ing HM extraction and refrigerated storage. However, storage and processing of DM 
may reduce some of its biological components and therefore result in a partial loss of its 
health benefits.  
Target group: The target population addressed in this thesis is the preterm newborn 
(i.e., newborns whose birth occurs <37 weeks gestational age). This group comprises 5-
10% of all birth in Europe, whereas in USA the rate is about 12–13%. 
Innovation: Currently, it remains a matter of debate whether the studies available in 
Literature adequately describe the impact of HoP and refrigerated storage on milk 
properties, and if the nutritional qualities of milk are preserved after these treatments. 
In fact, substantial discrepancies exist not only between the protocols applied in differ-
ent studies, but also between the standard operating procedures adopted by HMBs and 
the experimental methods reported in research protocols. 
The studies conducted in the present thesis were performed according to protocols 
designed to: 
i) match the actual procedures of storage, handling and processing of DM practiced by 
HMBs;  
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ii) provide results relevant for the actual clinical management of DM. Moreover, our 
studies determined the effects of HoP and refrigeration on specific biomarkers, 
which were not previously investigated.  
Activities: The results reported in the present thesis confirm that DM treatments can 
affect, to some extent, the milk components. In detail, differences in the protein profile 
after HoP were found, although only in 30% of the tested samples. The main detectable 
protein profile changes were observed in colostrum, thus further supporting the use of 
DM (since no evident changes were shown in mature milk). HoP did not cause any sig-
nificant change in the concentration of activin A and HO-1 in DM, also after correction 
for GA and maturation degree of the human milk. Conversely, HoP significantly de-
creased the concentration of the S100B protein. The finding is of relevance bearing in 
mind that role of the protein in CNS fetal and neonatal development. 
Concerning refrigeration procedures, our studies show that AM levels are affected 
by storage procedures (at 96-h from storage, up to 98% of the total peptide amount is 
degraded). 
Notably, the present thesis showed first the presence of activin A, HO-1 and AM in 
milk collected from preterm deliveries. Overall, results further support the clinical evi-
dence that DM retains the nutritional properties of HM, and provide further insight on 
which bioactive components these can be attributed to.  
Schedule and implementation: The present thesis contributes to a better understanding 
of the potential effects of storage on HM and primarily of HoP on DM. Our findings may 
also represent an opening view to: 
i) develop best practices balancing the treatments required to ensure microbiological 
safety of DM; 
ii) maintain DM benefits avoiding refrigerated storage for more than 24 hours; and  
iii) accept only mature milk (less susceptible to protein degradation) from donors. 
Future research should focus on improvements of milk processing in HMB (particu-
larly heat treatment) and on further evaluation of the potential clinical benefits of pro-
cessed and fortified DM. In particular, future studies must be aimed at improving the 
biological quality and safety of DM and should be:  
i) designed to investigate the pre-analytical stability of these components according to 
the storage procedures;  
ii) intended to evaluate innovative test technologies, such as metabolomics;  
iii) focused on new pasteurization techniques (high-temperature short-term pasteuriza-
tion, thermos-ultrasonic treatment, high-pressure processing, and Ohmic heat 
treatment); 
iv) aimed to evaluate analytical techniques able to assess the protein changes due to 
thermic treatments, as well as their interaction with sugars and lipids;  
v) designed to evaluate the effects of HoP on other biomarkers involved in growth and 
developing of newborns. 
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Moreover our findings open up to further investigations aimed at elucidating the pro-
tein stability during industrial processes for the preparation of artificial milk such as 
pasteurization and spray-drying, which have already been shown to affect milk compo-
sition and properties. 
Further data concerning the metabolic fate of the most important milk biomarkers 
in the gastro-enteric tract is needed to corroborate the hypothesis that these partici-
pate in the nutritional effects of milk and in its immuno-regulatory and trophic role for 
intestine and brain development. 
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